KR102104803B1 - Composition Comprising Gingenoside F2 and 4-α-D-Glucopyranosyloxy Benzyl Alcohol for Preventing or Improving Skin Wrinkle as Active Ingredient - Google Patents
Composition Comprising Gingenoside F2 and 4-α-D-Glucopyranosyloxy Benzyl Alcohol for Preventing or Improving Skin Wrinkle as Active Ingredient Download PDFInfo
- Publication number
- KR102104803B1 KR102104803B1 KR1020180073853A KR20180073853A KR102104803B1 KR 102104803 B1 KR102104803 B1 KR 102104803B1 KR 1020180073853 A KR1020180073853 A KR 1020180073853A KR 20180073853 A KR20180073853 A KR 20180073853A KR 102104803 B1 KR102104803 B1 KR 102104803B1
- Authority
- KR
- South Korea
- Prior art keywords
- benzyl alcohol
- alpha
- ginsenoside
- skin
- glucopyranosyloxy
- Prior art date
Links
- WVDDGKGOMKODPV-UHFFFAOYSA-N hydroxymethyl benzene Natural products OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 title claims abstract description 196
- -1 4-α-D-Glucopyranosyloxy Benzyl Chemical group 0.000 title claims abstract description 127
- 235000019445 benzyl alcohol Nutrition 0.000 title claims abstract description 97
- 230000037303 wrinkles Effects 0.000 title claims abstract description 61
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- 239000004480 active ingredient Substances 0.000 title claims abstract description 19
- SWIROVJVGRGSPO-UHFFFAOYSA-N Ginsenoside F2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O SWIROVJVGRGSPO-UHFFFAOYSA-N 0.000 claims abstract description 88
- AVTXSAWPGCSYFO-UHFFFAOYSA-N Ginsenoside Ia Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O AVTXSAWPGCSYFO-UHFFFAOYSA-N 0.000 claims abstract description 88
- SWIROVJVGRGSPO-JBVRGBGGSA-N ginsenoside F2 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SWIROVJVGRGSPO-JBVRGBGGSA-N 0.000 claims abstract description 88
- 230000014509 gene expression Effects 0.000 claims abstract description 33
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 claims abstract description 23
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims abstract description 23
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 claims abstract description 9
- 239000002537 cosmetic Substances 0.000 claims description 22
- 230000006872 improvement Effects 0.000 claims description 17
- 239000006210 lotion Substances 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 239000006071 cream Substances 0.000 claims description 10
- 235000013305 food Nutrition 0.000 claims description 6
- 235000016709 nutrition Nutrition 0.000 claims description 6
- 230000035764 nutrition Effects 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 5
- 239000006260 foam Substances 0.000 claims description 2
- 239000008269 hand cream Substances 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 230000037330 wrinkle prevention Effects 0.000 claims description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 18
- 238000004519 manufacturing process Methods 0.000 abstract description 17
- 102000004889 Interleukin-6 Human genes 0.000 abstract description 11
- 108090001005 Interleukin-6 Proteins 0.000 abstract description 11
- 210000002950 fibroblast Anatomy 0.000 abstract description 11
- 230000002500 effect on skin Effects 0.000 abstract description 8
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 abstract description 4
- 230000006378 damage Effects 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 69
- 230000000694 effects Effects 0.000 description 34
- 108010035532 Collagen Proteins 0.000 description 26
- 102000008186 Collagen Human genes 0.000 description 25
- 229920001436 collagen Polymers 0.000 description 25
- 150000001875 compounds Chemical class 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- BVJSUAQZOZWCKN-UHFFFAOYSA-N p-hydroxybenzyl alcohol Chemical compound OCC1=CC=C(O)C=C1 BVJSUAQZOZWCKN-UHFFFAOYSA-N 0.000 description 18
- 230000002401 inhibitory effect Effects 0.000 description 17
- 108010050808 Procollagen Proteins 0.000 description 15
- 210000001626 skin fibroblast Anatomy 0.000 description 15
- 230000014616 translation Effects 0.000 description 15
- 150000003839 salts Chemical class 0.000 description 14
- 239000000284 extract Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 239000000306 component Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 11
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 239000003925 fat Substances 0.000 description 11
- 235000019197 fats Nutrition 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 235000013376 functional food Nutrition 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 229940088594 vitamin Drugs 0.000 description 8
- 229930003231 vitamin Natural products 0.000 description 8
- 235000013343 vitamin Nutrition 0.000 description 8
- 239000011782 vitamin Substances 0.000 description 8
- 241001474374 Blennius Species 0.000 description 7
- 240000004371 Panax ginseng Species 0.000 description 7
- 235000002789 Panax ginseng Nutrition 0.000 description 7
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 7
- 235000003140 Panax quinquefolius Nutrition 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 235000008434 ginseng Nutrition 0.000 description 7
- 239000003642 reactive oxygen metabolite Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 5
- 102000016942 Elastin Human genes 0.000 description 5
- 108010014258 Elastin Proteins 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 238000013329 compounding Methods 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 229920002549 elastin Polymers 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000003020 moisturizing effect Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 238000001243 protein synthesis Methods 0.000 description 5
- 230000037394 skin elasticity Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 206010051246 Photodermatosis Diseases 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000008845 photoaging Effects 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 229960002920 sorbitol Drugs 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 4
- DHGBAFGZLVRESL-UHFFFAOYSA-N 14-methylpentadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C DHGBAFGZLVRESL-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 108010022452 Collagen Type I Proteins 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 3
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 3
- 102100022624 Glucoamylase Human genes 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108091054455 MAP kinase family Proteins 0.000 description 3
- 102000043136 MAP kinase family Human genes 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000005445 natural material Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 239000003002 pH adjusting agent Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 150000004804 polysaccharides Chemical class 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 description 2
- GECRRQVLQHRVNH-MRCUWXFGSA-N 2-octyldodecyl (z)-octadec-9-enoate Chemical compound CCCCCCCCCCC(CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC GECRRQVLQHRVNH-MRCUWXFGSA-N 0.000 description 2
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 2
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 2
- 235000019489 Almond oil Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- BMFMQGXDDJALKQ-BYPYZUCNSA-N Argininic acid Chemical compound NC(N)=NCCC[C@H](O)C(O)=O BMFMQGXDDJALKQ-BYPYZUCNSA-N 0.000 description 2
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 2
- ZCTQGTTXIYCGGC-UHFFFAOYSA-N Benzyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OCC1=CC=CC=C1 ZCTQGTTXIYCGGC-UHFFFAOYSA-N 0.000 description 2
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 2
- 108010059892 Cellulase Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- 108010025880 Cyclomaltodextrin glucanotransferase Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 2
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 102100023132 Transcription factor Jun Human genes 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000008168 almond oil Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000010775 animal oil Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 125000002351 beta-D-glucopyranosyloxy group Chemical group 0.000 description 2
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- SHZIWNPUGXLXDT-UHFFFAOYSA-N caproic acid ethyl ester Natural products CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 229940106157 cellulase Drugs 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- RAPXDXJBAYUBHI-UHFFFAOYSA-N decyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCCCCCC RAPXDXJBAYUBHI-UHFFFAOYSA-N 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- MVLVMROFTAUDAG-UHFFFAOYSA-N ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC MVLVMROFTAUDAG-UHFFFAOYSA-N 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000020710 ginseng extract Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229960002900 methylcellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 2
- 235000019488 nut oil Nutrition 0.000 description 2
- 239000010466 nut oil Substances 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- OQILCOQZDHPEAZ-UHFFFAOYSA-N octyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- ZQBAKBUEJOMQEX-UHFFFAOYSA-N phenyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 ZQBAKBUEJOMQEX-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 230000036560 skin regeneration Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 150000003408 sphingolipids Chemical class 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 230000037373 wrinkle formation Effects 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- WFXHUBZUIFLWCV-UHFFFAOYSA-N (2,2-dimethyl-3-octanoyloxypropyl) octanoate Chemical compound CCCCCCCC(=O)OCC(C)(C)COC(=O)CCCCCCC WFXHUBZUIFLWCV-UHFFFAOYSA-N 0.000 description 1
- DEQUKPCANKRTPZ-UHFFFAOYSA-N (2,3-dihydroxyphenyl)-phenylmethanone Chemical compound OC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1O DEQUKPCANKRTPZ-UHFFFAOYSA-N 0.000 description 1
- BOCBOJPUWMTAJB-UHFFFAOYSA-N (2-butylphenyl) 2-hydroxybenzoate Chemical compound CCCCC1=CC=CC=C1OC(=O)C1=CC=CC=C1O BOCBOJPUWMTAJB-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- OVYMWJFNQQOJBU-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl octanoate Chemical compound CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC OVYMWJFNQQOJBU-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GLXBPZNFNSLJBS-UHFFFAOYSA-N 11-methyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCCCCCCCCC(C)C GLXBPZNFNSLJBS-UHFFFAOYSA-N 0.000 description 1
- 229940114072 12-hydroxystearic acid Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- OUZOBPPZPCBJAR-UHFFFAOYSA-N 14-methylpentadecyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C OUZOBPPZPCBJAR-UHFFFAOYSA-N 0.000 description 1
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
- YICVJSOYNBZJAK-UHFFFAOYSA-N 14-methylpentadecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C YICVJSOYNBZJAK-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- WPIOBXGJZUSKGK-UHFFFAOYSA-N 16-methylheptadecyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC(C)C WPIOBXGJZUSKGK-UHFFFAOYSA-N 0.000 description 1
- SAMYFBLRCRWESN-UHFFFAOYSA-N 16-methylheptadecyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC(C)C SAMYFBLRCRWESN-UHFFFAOYSA-N 0.000 description 1
- MVUWRLHKGKEGSS-UHFFFAOYSA-N 16-methylheptadecyl octanoate Chemical compound CCCCCCCC(=O)OCCCCCCCCCCCCCCCC(C)C MVUWRLHKGKEGSS-UHFFFAOYSA-N 0.000 description 1
- VRBHTEGUHVNKEA-UHFFFAOYSA-N 16-methylheptadecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC(C)C VRBHTEGUHVNKEA-UHFFFAOYSA-N 0.000 description 1
- FUTGDWNFCMWSJT-UHFFFAOYSA-N 2,3-bis(14-methylpentadecanoyloxy)propyl 14-methylpentadecanoate Chemical compound CC(C)CCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCC(C)C FUTGDWNFCMWSJT-UHFFFAOYSA-N 0.000 description 1
- JNAYPSWVMNJOPQ-UHFFFAOYSA-N 2,3-bis(16-methylheptadecanoyloxy)propyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCC(C)C JNAYPSWVMNJOPQ-UHFFFAOYSA-N 0.000 description 1
- XFOQWQKDSMIPHT-UHFFFAOYSA-N 2,3-dichloro-6-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Cl)C(Cl)=N1 XFOQWQKDSMIPHT-UHFFFAOYSA-N 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N 2-Ethylhexanoic acid Chemical compound CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- NFIHXTUNNGIYRF-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate Chemical compound CCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCC NFIHXTUNNGIYRF-UHFFFAOYSA-N 0.000 description 1
- GLCFQKXOQDQJFZ-UHFFFAOYSA-N 2-ethylhexyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(CC)CCCC GLCFQKXOQDQJFZ-UHFFFAOYSA-N 0.000 description 1
- JGUMTYWKIBJSTN-UHFFFAOYSA-N 2-ethylhexyl 4-[[4,6-bis[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 JGUMTYWKIBJSTN-UHFFFAOYSA-N 0.000 description 1
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 1
- WDEHKPUUQDUYGZ-UHFFFAOYSA-N 2-methyl-1,3-thiazole 2H-tetrazole Chemical compound C=1N=NNN=1.CC1=NC=CS1 WDEHKPUUQDUYGZ-UHFFFAOYSA-N 0.000 description 1
- LEEDMQGKBNGPDN-UHFFFAOYSA-N 2-methylnonadecane Chemical compound CCCCCCCCCCCCCCCCCC(C)C LEEDMQGKBNGPDN-UHFFFAOYSA-N 0.000 description 1
- HTNFLUQQANUSLR-UHFFFAOYSA-N 2-octanoyloxyethyl octanoate Chemical compound CCCCCCCC(=O)OCCOC(=O)CCCCCCC HTNFLUQQANUSLR-UHFFFAOYSA-N 0.000 description 1
- PTPDZZWUOHQSLG-UHFFFAOYSA-N 2-octyldodecyl 2,2-dimethylpropanoate Chemical compound CCCCCCCCCCC(COC(=O)C(C)(C)C)CCCCCCCC PTPDZZWUOHQSLG-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- YPIFGDQKSSMYHQ-UHFFFAOYSA-M 7,7-dimethyloctanoate Chemical compound CC(C)(C)CCCCCC([O-])=O YPIFGDQKSSMYHQ-UHFFFAOYSA-M 0.000 description 1
- ODMZDMMTKHXXKA-QXMHVHEDSA-N 8-methylnonyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCCCCCCC(C)C ODMZDMMTKHXXKA-QXMHVHEDSA-N 0.000 description 1
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- JIAVUMAJCIDZOU-UHFFFAOYSA-N CCCCCCCCCC(CCCCCC)OC(=O)CCCCCC(C)(C)C Chemical compound CCCCCCCCCC(CCCCCC)OC(=O)CCCCCC(C)(C)C JIAVUMAJCIDZOU-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- RDOFJDLLWVCMRU-UHFFFAOYSA-N Diisobutyl adipate Chemical compound CC(C)COC(=O)CCCCC(=O)OCC(C)C RDOFJDLLWVCMRU-UHFFFAOYSA-N 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- GWFGDXZQZYMSMJ-UHFFFAOYSA-N Octadecansaeure-heptadecylester Natural products CCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC GWFGDXZQZYMSMJ-UHFFFAOYSA-N 0.000 description 1
- RJECHNNFRHZQKU-UHFFFAOYSA-N Oelsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCC=CCCCCCCCC)C2 RJECHNNFRHZQKU-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 108010059820 Polygalacturonase Proteins 0.000 description 1
- NKSOSPOXQKNIKJ-CLFAGFIQSA-N Polyoxyethylene dioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCOC(=O)CCCCCCC\C=C/CCCCCCCC NKSOSPOXQKNIKJ-CLFAGFIQSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- PRLUQOOFPFWUKQ-KKTNLPSRSA-N [(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl] (z)-octadec-9-enoate Chemical compound C1C[C@@H]2[C@@]3(C)CC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C[C@@H]3CC[C@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@]21C PRLUQOOFPFWUKQ-KKTNLPSRSA-N 0.000 description 1
- XKMYWNHZAQUEPY-YZGJEOKZSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 12-hydroxyoctadecanoate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCC(O)CCCCCC)C1 XKMYWNHZAQUEPY-YZGJEOKZSA-N 0.000 description 1
- JBBRZDLNVILTDL-XNTGVSEISA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 16-methylheptadecanoate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCC(C)C)C1 JBBRZDLNVILTDL-XNTGVSEISA-N 0.000 description 1
- WUBKCBOQNXUQDU-UHFFFAOYSA-N [2-(dihydroxymethoxy)phenyl]-phenylmethanone Chemical compound OC(O)OC1=CC=CC=C1C(=O)C1=CC=CC=C1 WUBKCBOQNXUQDU-UHFFFAOYSA-N 0.000 description 1
- SVRHJWALMLOXMI-UHFFFAOYSA-N [2-(dihydroxymethoxy)phenyl]-phenylmethanone;sodium Chemical compound [Na].OC(O)OC1=CC=CC=C1C(=O)C1=CC=CC=C1 SVRHJWALMLOXMI-UHFFFAOYSA-N 0.000 description 1
- YRXGUZPUZBCGST-UHFFFAOYSA-N [2-(hydroxymethoxy)phenyl]-phenylmethanone Chemical compound OCOC1=CC=CC=C1C(=O)C1=CC=CC=C1 YRXGUZPUZBCGST-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- IZQZNLBFNMTRMF-UHFFFAOYSA-N acetic acid;phosphoric acid Chemical compound CC(O)=O.OP(O)(O)=O IZQZNLBFNMTRMF-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- HGKOWIQVWAQWDS-UHFFFAOYSA-N bis(16-methylheptadecyl) 2-hydroxybutanedioate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CC(O)C(=O)OCCCCCCCCCCCCCCCC(C)C HGKOWIQVWAQWDS-UHFFFAOYSA-N 0.000 description 1
- WMNULTDOANGXRT-UHFFFAOYSA-N bis(2-ethylhexyl) butanedioate Chemical compound CCCCC(CC)COC(=O)CCC(=O)OCC(CC)CCCC WMNULTDOANGXRT-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- DHAZIUXMHRHVMP-UHFFFAOYSA-N butyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCC DHAZIUXMHRHVMP-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- SIHHLZPXQLFPMC-UHFFFAOYSA-N chloroform;methanol;hydrate Chemical compound O.OC.ClC(Cl)Cl SIHHLZPXQLFPMC-UHFFFAOYSA-N 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 229940072104 cholesteryl hydroxystearate Drugs 0.000 description 1
- 229940073724 cholesteryl isostearate Drugs 0.000 description 1
- RJECHNNFRHZQKU-RMUVNZEASA-N cholesteryl oleate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C1 RJECHNNFRHZQKU-RMUVNZEASA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000000490 cosmetic additive Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- UPWQHKLZCDYJOU-UHFFFAOYSA-N decanoic acid;2,2-dimethylpropane-1,3-diol Chemical compound OCC(C)(C)CO.CCCCCCCCCC(O)=O.CCCCCCCCCC(O)=O UPWQHKLZCDYJOU-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- BOUIEBMBWBCUPB-UHFFFAOYSA-N decyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCCCCCCCC BOUIEBMBWBCUPB-UHFFFAOYSA-N 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229940031769 diisobutyl adipate Drugs 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 229940031569 diisopropyl sebacate Drugs 0.000 description 1
- MIMDHDXOBDPUQW-UHFFFAOYSA-N dioctyl decanedioate Chemical compound CCCCCCCCOC(=O)CCCCCCCCC(=O)OCCCCCCCC MIMDHDXOBDPUQW-UHFFFAOYSA-N 0.000 description 1
- XFKBBSZEQRFVSL-UHFFFAOYSA-N dipropan-2-yl decanedioate Chemical compound CC(C)OC(=O)CCCCCCCCC(=O)OC(C)C XFKBBSZEQRFVSL-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- WPUMTJGUQUYPIV-JIZZDEOASA-L disodium (S)-malate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](O)CC([O-])=O WPUMTJGUQUYPIV-JIZZDEOASA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- SNPLKNRPJHDVJA-UHFFFAOYSA-N dl-panthenol Chemical compound OCC(C)(C)C(O)C(=O)NCCCO SNPLKNRPJHDVJA-UHFFFAOYSA-N 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- QQQMUBLXDAFBRH-UHFFFAOYSA-N dodecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)O QQQMUBLXDAFBRH-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 description 1
- 229940031016 ethyl linoleate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 108010093305 exopolygalacturonase Proteins 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 235000019249 food preservative Nutrition 0.000 description 1
- 239000005452 food preservative Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 229960002389 glycol salicylate Drugs 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- DWMMZQMXUWUJME-UHFFFAOYSA-N hexadecyl octanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC DWMMZQMXUWUJME-UHFFFAOYSA-N 0.000 description 1
- QAKXLTNAJLFSQC-UHFFFAOYSA-N hexadecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC QAKXLTNAJLFSQC-UHFFFAOYSA-N 0.000 description 1
- FPMPNVIMFPEKRN-UHFFFAOYSA-N hexyl 16-methylheptadecanoate Chemical compound CCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C FPMPNVIMFPEKRN-UHFFFAOYSA-N 0.000 description 1
- 229940100463 hexyl laurate Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 229940072106 hydroxystearate Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940078568 isocetyl myristate Drugs 0.000 description 1
- 229940078545 isocetyl stearate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940060384 isostearyl isostearate Drugs 0.000 description 1
- 229940113915 isostearyl palmitate Drugs 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000003903 lactic acid esters Chemical class 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000012035 limiting reagent Substances 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- LAQFLZHBVPULPL-UHFFFAOYSA-N methyl(phenyl)silicon Chemical compound C[Si]C1=CC=CC=C1 LAQFLZHBVPULPL-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229940078812 myristyl myristate Drugs 0.000 description 1
- GQEZCXVZFLOKMC-UHFFFAOYSA-N n-alpha-hexadecene Natural products CCCCCCCCCCCCCCC=C GQEZCXVZFLOKMC-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- PIUVNPNBPWVVKZ-UHFFFAOYSA-N octadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC PIUVNPNBPWVVKZ-UHFFFAOYSA-N 0.000 description 1
- NKBWPOSQERPBFI-UHFFFAOYSA-N octadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC NKBWPOSQERPBFI-UHFFFAOYSA-N 0.000 description 1
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
- 229960003921 octisalate Drugs 0.000 description 1
- WCJLCOAEJIHPCW-UHFFFAOYSA-N octyl 2-hydroxybenzoate Chemical compound CCCCCCCCOC(=O)C1=CC=CC=C1O WCJLCOAEJIHPCW-UHFFFAOYSA-N 0.000 description 1
- YPMOZWCBANATQH-UHFFFAOYSA-N octyl 7-methyloctanoate Chemical compound CCCCCCCCOC(=O)CCCCCC(C)C YPMOZWCBANATQH-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- IIGMITQLXAGZTL-UHFFFAOYSA-N octyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCC IIGMITQLXAGZTL-UHFFFAOYSA-N 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 229940048862 octyldodecyl neopentanoate Drugs 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000010702 perfluoropolyether Substances 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 229960000969 phenyl salicylate Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- LYKRPDCJKSXAHS-UHFFFAOYSA-N phenyl-(2,3,4,5-tetrahydroxyphenyl)methanone Chemical compound OC1=C(O)C(O)=CC(C(=O)C=2C=CC=CC=2)=C1O LYKRPDCJKSXAHS-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 description 1
- 229940033329 phytosphingosine Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- XEIOPEQGDSYOIH-MURFETPASA-N propan-2-yl (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC(C)C XEIOPEQGDSYOIH-MURFETPASA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229940116422 propylene glycol dicaprate Drugs 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000010499 rapseed oil Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000019265 sodium DL-malate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000001394 sodium malate Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical class [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- BORJONZPSTVSFP-UHFFFAOYSA-N tetradecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCCCOC(=O)C(C)O BORJONZPSTVSFP-UHFFFAOYSA-N 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 1
- APVVRLGIFCYZHJ-UHFFFAOYSA-N trioctyl 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound CCCCCCCCOC(=O)CC(O)(C(=O)OCCCCCCCC)CC(=O)OCCCCCCCC APVVRLGIFCYZHJ-UHFFFAOYSA-N 0.000 description 1
- COXJMKGEQAWXNP-UHFFFAOYSA-N tris(14-methylpentadecyl) 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound CC(C)CCCCCCCCCCCCCOC(=O)CC(O)(C(=O)OCCCCCCCCCCCCCC(C)C)CC(=O)OCCCCCCCCCCCCCC(C)C COXJMKGEQAWXNP-UHFFFAOYSA-N 0.000 description 1
- RHNXTZDKMRCKKT-UHFFFAOYSA-N tris(6-methylheptyl) 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound CC(C)CCCCCOC(=O)CC(O)(C(=O)OCCCCCC(C)C)CC(=O)OCCCCCC(C)C RHNXTZDKMRCKKT-UHFFFAOYSA-N 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 239000003021 water soluble solvent Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 150000008135 α-glycosides Chemical class 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
본 발명은 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올(4-α-D-glucopyranosyloxy benzyl alcohol)을 유효성분으로 포함하는 피부 주름 예방 또는 개선용 조성물에 관한 것이다.
본 발명의 조성물은 인간 진피 섬유 아세포들에서 MMP-1 단백질의 발현을 억제하고, 타입 Ⅰ 프로콜라겐의 생성을 증가시키며, IL-6 단백질의 발현을 억제함으로써, 피부 주름의 발생을 예방하고, 손상된 피부의 주름을 개선하는데 시너지 효과를 나타낸다. 종합적으로, 본 발명의 조성물은 피부 주름을 예방하고 크게 개선할 수 있다. The present invention relates to a composition for preventing or improving skin wrinkles comprising ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol as an active ingredient.
The composition of the present invention inhibits the expression of MMP-1 protein in human dermal fibroblasts, increases the production of type I procollagen, and suppresses the expression of IL-6 protein, thereby preventing the occurrence of skin wrinkles and damage It has a synergistic effect in improving wrinkles on the skin. Overall, the composition of the present invention can prevent and greatly improve skin wrinkles.
Description
본 발명은 피부 주름 예방 또는 개선 개선용 조성물에 관한 것으로, 더욱 구체적으로 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올을 유효성분으로 함유하는 피부 주름 예방 또는 개선용 조성물에 관한 것이다.The present invention relates to a composition for preventing or improving skin wrinkles, and more specifically, to a composition for preventing or improving skin wrinkles containing ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol as active ingredients. It is about.
피부 주름은 피부 수분함량, 콜라겐 함량 및 외부 환경에 대한 면역력 등 여러 가지 요소들에 의해 영향을 받는 것으로 알려져 있으며, 이중 주름의 형성에 가장 큰 영향을 미치는 것은 콜라겐의 생성량 및 콜라겐 분해 효소인 콜라게네이즈의 발현과 활성이다. Skin wrinkles are known to be affected by various factors such as skin moisture content, collagen content, and immunity to the external environment, and the biggest influence on the formation of double wrinkles is collagen, the amount of collagen produced and collagen degrading enzyme It is the expression and activity of naze.
콜라겐은 피부 진피층에 존재하는데, 피부 전체 건조 중량의 약 70%에서 80%를 차지하는 엘라스틴과 함께 피부에 탄력을 부여하는 주요 성분으로 알려져 있다. 콜라겐은 자연 노화에 따른 세포 활성 저하와 같은 내부 요인에 의해 감소하고, 여러 유해 환경에서의 스트레스 증가나 태양 광선에 의한 활성 산소 종의 증가와 같은 외부 요인에 의하여 생합성이 감소하거나, 분해가 촉진된다.Collagen is present in the dermal layer of the skin, and is known as a major component that gives skin elasticity with elastin accounting for about 70% to 80% of the total dry weight of the skin. Collagen is reduced by internal factors such as decreased cell activity due to natural aging, and biosynthesis is reduced or decomposition is promoted by external factors such as increased stress in various harmful environments or increased free radical species caused by sunlight. .
한편, 활성산소종(reactive oxygen species, ROS)의 과생산은 UVB 노출 환경에서 보고된 바 있고, UVB 노출과 연관된 신호전달 체계는 MAPKs(mitogen activated protein kinases), ERK(extracellular signal-regulated kinase), p38 카이나아제, 및 JNK(c-Jun amino-terminal kinase) 등의 단백질과 관련되어 있는데, NF-ĸB 및 AP-1 전사인자의 발현증가를 유도한다. 또한, AP-1 단백질은 MMP(matrix metallo-proteinase) 유전자의 활성과 관련되어 있고, NF-ĸB 단백질은 인터루킨과 같은 전염증 사이토카인(proinflammatory cytokines)의 발현에 영향을 미친다. Meanwhile, overproduction of reactive oxygen species (ROS) has been reported in a UVB exposure environment, and signaling systems associated with UVB exposure are mitogen activated protein kinases (MAPKs), extracellular signal-regulated kinase (ERK), It is associated with proteins such as p38 kinase and JNK (c-Jun amino-terminal kinase), which induces an increase in the expression of NF-ĸB and AP-1 transcription factors. In addition, the AP-1 protein is associated with the activity of the matrix metallo-proteinase (MMP) gene, and the NF-ĸB protein affects the expression of proinflammatory cytokines such as interleukin.
노화된 피부에서 콜라겐 및 엘라스틴의 붕괴는 주로 MMP 단백질과 같은 그 분해 효소의 증가된 발현으로 야기된다. 또한, 전염증 사이토카인은 콜라겐의 합성을 방해하고, 콜라겐의 붕괴를 촉진한다. 타입 I 콜라겐은 연결 조직의 세포외 기질에서 가장 풍부한 단백질이다. 세포외 기질에는 타입 III, V, 및 VII 콜라겐, 엘라스틴, 프로테오글라이칸, 피브로넥틴과 같은 다른 유형의 단백질을 포함한다. The breakdown of collagen and elastin in aged skin is mainly caused by increased expression of its degrading enzymes such as MMP protein. In addition, pro-inflammatory cytokines interfere with the synthesis of collagen and promote the breakdown of collagen. Type I collagen is the most abundant protein in the extracellular matrix of connective tissue. Extracellular matrix includes other types of proteins such as type III, V, and VII collagen, elastin, proteoglycans, fibronectin.
타입 I 콜라겐 단백질의 발현 수준을 조절하는 것은 피부 광노화를 예방하는데 있어서 가장 중요한 인자이다. UVB의 조사는 TGF-β/Smad 신호전달 체계의 억제를 통해 피부 섬유아세포에서 콜라겐 전구체인 프로콜라겐(procollagen)의 발현을 감소시키게 된다. 또한, TGF-β1 신호전달 체계는 인간 피부 섬유아세포에서 세포외 기질의 합성을 조절하는 중요한 인자의 하나이다. Controlling the expression level of type I collagen protein is the most important factor in preventing skin photoaging. Irradiation of UVB reduces the expression of the collagen precursor procollagen in skin fibroblasts through inhibition of the TGF-β / Smad signaling system. In addition, the TGF-β1 signaling system is one of the important factors that regulate the synthesis of extracellular matrix in human skin fibroblasts.
따라서, AP-1 및 MAPKs 인자에 의해 조절되는 활성산소종(ROS)의 생성, 및 MMPs, ILs, TGF-β, 및 타입 I 프로콜라겐의 발현은 피부 광노화 연구에 있어서 유용한 마커로 작용한다. Thus, the production of reactive oxygen species (ROS), which is regulated by the factors AP-1 and MAPKs, and the expression of MMPs, ILs, TGF-β, and type I procollagens serve as useful markers in skin photoaging studies.
이와 같이 콜라겐 감소를 저해하여 피부 주름 개선에 효과가 있는 천연물질을 탐색하고자 하는 여러 다양한 시도가 있었다. 콜라겐의 주름 개선 효과를 이용하기 위하여 화장품 또는 연고 등과 같은 피부 외용제 조성물에 콜라겐을 배합한 제품들이 출시되었으나, 이들 제품은 콜라겐 자체를 피부 표면에 바르는 것으로 고분자 물질인 콜라겐의 경피 흡수가 어려워 본질적인 주름 개선 효과를 나타낼 수 없었다. 이러한 문제를 해결하기 위하여 콜라겐 합성 촉진물질에 관한 관심이 높아졌으며, 종래 알려진 콜라겐 합성 촉진물질로는 비타민C, 레티노익산, 형질전환 생장인자(transforming growth factor, TGF), 동물 태반 유래의 단백질(JP08-231370), 베툴린산(betulinic acid, JP08-208424), 클로렐라 추출물(JP09-40523, JP10-36283, 섬유아세포 증식 촉진작용) 등이 있다. 그러나 상기 물질은 피부 적용시 자극과 발적 등 안전성 문제로 사용량에 제한이 있거나, 그 효과가 미미하여 실질적으로 주름 개선 효과를 기대할 수 없다는 문제점이 있었다. 따라서 종래 주름 개선용 조성물보다 생체에 안전하고 주름 개선 효과가 높은 새로운 주름 개선 조성물의 개발이 절실히 요구되고 있다.As described above, various attempts have been made to explore natural substances that are effective in improving skin wrinkles by inhibiting collagen reduction. To take advantage of the wrinkle improvement effect of collagen, products containing collagen in a composition for external application for skin such as cosmetics or ointment have been released, but these products apply collagen itself to the skin surface, making it difficult to percutaneously absorb collagen, a polymer material, to improve essential wrinkles. The effect could not be exhibited. In order to solve these problems, interest in collagen synthesis promoters has increased, and known collagen synthesis promoters include vitamin C, retinoic acid, transforming growth factor (TGF), and protein derived from animal placenta (JP08 -231370), betulinic acid (betulinic acid, JP08-208424), chlorella extract (JP09-40523, JP10-36283, fibroblast proliferation promoting action) and the like. However, when the skin was applied, there was a problem in that there was a limitation in the amount of use due to safety problems such as irritation and redness, or the effect was insignificant, so that the effect of improving wrinkles could not be expected. Therefore, there is an urgent need for the development of a new wrinkle improving composition that is more bio-safe and has a higher wrinkle improving effect than a conventional wrinkle improving composition.
한편, 홍삼은 오래전부터 한방에서는 약용으로 사용되는 소재로, 홍삼의 피부주름 개선 효과와 관련하여, 한국공개특허공보 제10-2011-0060001호, 한국공개특허공보 제10-2011-0048699호, 한국공개특허공보 제10-2011-063912호, 한국공개특허공보 제10-2011-0063916호 등은 홍삼 및 홍삼 유래 사포닌이 갖는 피부 상태 개선 기능 등에 대하여 공개하고 있다. 또한, 한국특허등록공보 제10-1469810호, 한국특허등록공보 제10-1460569호 등에서는 홍삼의 유효성분 중 하나인 진세노사이드 F2가 갖는 주름 개선, 피부 미백 및 여드름 개선 등의 효과를 개시하고 있다.On the other hand, red ginseng is a material that has been used for medicinal use in oriental medicine for a long time, and in relation to the skin wrinkle improvement effect of red ginseng, Korean Patent Publication No. 10-2011-0060001, Korean Patent Publication No. 10-2011-0048699, Korea Korean Patent Publication No. 10-2011-063912, Korean Patent Publication No. 10-2011-0063916, etc. disclose the function of improving the skin condition of red ginseng and red ginseng-derived saponins. In addition, Korean Patent Registration No. 10-1469810, Korean Patent Registration No. 10-1460569, etc. disclose the effects of wrinkle improvement, skin whitening and acne improvement of ginsenoside F2, one of the active ingredients of red ginseng, and have.
또한, 본 발명자들이 연구하여 출원한 특허공개 제10-2016-0167064호는 천마에서 가스트로다이제닌을 분리하고 글루코오스를 α-글리코시드 형태로 결합시켜, α-가스트로딘(4-알파-D-글루코피라노실록시 벤질 알코올) 형태로 가공 및 변형하여 생성된 신물질이 갖는 주름 개선 효과가 공지되어 있다. In addition, Patent Publication No. 10-2016-0167064, which has been studied and applied by the present inventors, separates gastrodigenin from cheonma and binds glucose in the form of α-glycoside, thereby causing α-gastrodine (4-alpha-D- Glucopyranosyloxy benzyl alcohol) has been known to improve the wrinkles of new substances produced by processing and modification.
상기와 같은 배경 아래, 본 발명자들은 지금까지 피부 주름 개선에 뛰어난 효과가 있는 것으로 알려진 다양한 성분들을 대상으로 이들의 시너지 효과를 극대화할 수 있도록 예의 연구 노력한 결과, 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올의 조합이 UVB 조사에 의해 유도된 인간 섬유아세포(human dermal fibroblasts, NHDFs)의 광노화에 대응하여 피부 주름 예방 및 개선에 뛰어난 효과가 있음을 확인하고, 본 발명을 완성하게 되었다.Under the above-mentioned background, the present inventors have conducted extensive research to maximize their synergistic effect on various ingredients known to have excellent effects on skin wrinkle improvement so far, as a result of ginsenoside F2 and 4-alpha-D -Confirmed that the combination of glucopyranosyloxy benzyl alcohol has an excellent effect on preventing and improving skin wrinkles in response to photoaging of human dermal fibroblasts (NHDFs) induced by UVB irradiation, and completed the present invention. Was done.
따라서, 본 발명의 주된 목적은 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올을 유효성분으로 하여 피부 주름의 예방 또는 개선에 뛰어난 효과가 있는 조성물을 제공하는 데 있다.Therefore, the main object of the present invention is to provide a composition having excellent effect in preventing or improving skin wrinkles by using ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol as active ingredients.
본 발명의 한 양태에 따르면, 본 발명은 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올(4-α-D-glucopyranosyloxy benzyl alcohol)을 유효성분으로 포함하는 피부 주름 예방 또는 개선용 화장료 조성물을 제공한다.According to one aspect of the present invention, the present invention is ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol (4-α-D-glucopyranosyloxy benzyl alcohol) as an active ingredient to prevent skin wrinkles or Provided is a cosmetic composition for improvement.
본 발명자들은 피부 주름개선 및 피부노화 방지에 효능이 있는 물질을 찾고자 여러 가지 천연물질들 중에서 피부 주름 개선에 유효한 물질을 동정하고, 이들이 갖는 시너지 효과를 극대화할 수 있는 혼합비율을 찾기 위해 예의 연구노력한 결과, 홍삼에서 유래한 진세노사이드 F2와, 천마에서 유래한 가스트로다이제닌(Gastrodigenin, 4-Hydroxybenzyl alcohol)에 셀로비오스(cellobiose)를 당 공여체로 하여 생성한 4-알파-D-글루코피라노실록시 벤질 알코올(4-α-D-glucopyranosyloxy benzyl alcohol, α-가스트로딘)의 조합이 피부 주름 예방 및 개선에 시너지 효과를 보이는 것을 발견하였고, 또한 피부에 적용시 안전성에도 문제가 없음을 확인하였다.The present inventors identify substances that are effective in improving skin wrinkles among various natural substances in order to find substances that are effective in improving skin wrinkles and preventing skin aging, and have worked hard to find a mixing ratio that can maximize their synergistic effects. As a result, ginsenoside F2 derived from red ginseng and 4-alpha-D-glucopyrano produced by cellobiose as a sugar donor to gastrodigenin (4-Hydroxybenzyl alcohol) derived from Cheonma It was found that the combination of siloxy benzyl alcohol (4-α-D-glucopyranosyloxy benzyl alcohol, α-gastrodine) showed a synergistic effect on the prevention and improvement of skin wrinkles, and also confirmed that there was no safety problem when applied to the skin. .
본 발명의 ‘진세노사이드 F2(ginsenoside F2)’는 인삼, 홍삼, 백삼, 수삼, 미삼 및 산삼배양근 등에 함유된 인삼 사포닌(Saponin)의 일종으로 ‘(20S)-3β-(β-D-Glucopyranosyloxy)-20-(β-D-glucopyranosyloxy)dammar-24-ene-12β-ol’로 나타낼 수 있으며, 분자식은 C42H72O13이고, 분자량은 785.01인 물질이며, 하기 [화학식 1]의 분자구조를 갖는다.'Ginsenoside F2 (ginsenoside F2)' of the present invention is a type of ginseng saponin contained in ginseng, red ginseng, white ginseng, ginseng, rice ginseng, and wild ginseng culture roots, such as' (20S) -3β- (β-D-Glucopyranosyloxy ) -20- (β-D-glucopyranosyloxy) dammar-24-ene-12β-ol ', the molecular formula is C 42 H 72 O 13 , the molecular weight is 785.01, the substance of the following [Formula 1] It has a structure.
[화학식 1][Formula 1]
또한, 본 발명의 상기 화합물 ‘4-알파-D-글루코피라노실록시 벤질 알코올(4-α-D-glucopyranosyloxy benzyl alcohol)’의 분자식은 C13H18O7이고, 분자량이 286.28인 물질이며, 하기 [화학식 2]의 분자구조를 갖는다.In addition, the molecular formula of the compound '4-alpha-D-glucopyranosyloxy benzyl alcohol (4-α-D-glucopyranosyloxy benzyl alcohol)' of the present invention is a material having a molecular weight of C 13 H 18 O 7 and a molecular weight of 286.28 , Has the molecular structure of the following [Formula 2].
[화학식 2][Formula 2]
상기 4-알파-D-글루코피라노실록시 벤질 알코올(4-α-D-glucopyranosyloxy benzyl alcohol)은 천마에 함유된 천연성분인 가스트로다이제닌(Gastrodigenin, 4-Hydroxybenzyl alcohol)을 당 수용체로 하고, 셀로비오스(cellobiose)를 당 공여체로 하여, 셀룰라아제(cellulase), α-글루코시다아제(Glucosidase) 등의 효소를 처리를 통하여 α-글리코시드 결합을 형성시켜 제조할 수 있으며, 본 명세서에서 상기 용어 ‘4-알파-D-글루코피라노실록시 벤질 알코올’과 a-가스트로딘은 동일한 의미로 사용된다. 상기 가스트로다이제닌에서 4-알파-D-글루코피라노실록시 벤질 알코올로의 전환 방법은 발명자들이 출원한 특허출원 제10-2016-0167064호에 상세히 개시되어 있다. The 4-alpha-D-glucopyranosyloxy benzyl alcohol (4-α-D-glucopyranosyloxy benzyl alcohol) is a natural ingredient contained in cheonma gastrodigenin (Gastrodigenin, 4-Hydroxybenzyl alcohol) as a sugar acceptor , Cellobiose (cellobiose) as a sugar donor, cellulase (cellulase), α-glucosidase (Glucosidase), etc. can be prepared by forming an α-glycoside bond through treatment with enzymes, and in this specification, the term '4-alpha-D-glucopyranosyloxy benzyl alcohol' and a-gastrodine are used interchangeably. The method for converting gastrodigenin to 4-alpha-D-glucopyranosyloxy benzyl alcohol is disclosed in detail in Patent Application No. 10-2016-0167064 filed by the inventors.
또한, 본 발명에서 제시하는 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올은 특별한 언급이 없는 한, 진세노사이드 F2 또는 4-알파-D-글루코피라노실록시 벤질 알코올의 염을 모두 포함하며, 주름 개선 소재로 사용될 수 있다. 상기 진세노사이드 F2 또는 4-알파-D-글루코피라노실록시 벤질 알코올이 염의 형태로 사용하는 경우, 유효성분인 진세노사이드 F2 또는 4-알파-D-글루코피라노실록시 벤질 알코올에 관하여 존재하는 염 중에서 항박테리아제, 항진균제, 식품보존첨가제, 화장품 첨가제 또는 항진균용 농약으로서 허용되는 염을 선택하면 양호하다. 대표적으로, 상기 염으로는 염산염, 황산염, 질산염, 인산염, 브롬화수소산염, 요드화수소산염 등의 무기산의 산부가염, 또는 아세트산염, 옥살산염, 마론산염, 숙식산염, 마레인산염, 푸말산염, 젖산염, 말산염, 시트르산염, 타르타르산염, 메탄술폰산염, 에탄술폰산염 등의 유기산의 부가염을 들 수 있다. In addition, the ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohols presented in the present invention are ginsenoside F2 or 4-alpha-D-glucopyranosyloxy benzyl alcohol unless otherwise specified. It contains all of the salt, and can be used as a wrinkle improving material. When the ginsenoside F2 or 4-alpha-D-glucopyranosyloxy benzyl alcohol is used in the form of a salt, the active ingredient ginsenoside F2 or 4-alpha-D-glucopyranosyloxy benzyl alcohol It is preferable to select an acceptable salt as an antibacterial agent, antifungal agent, food preservative additive, cosmetic additive, or antifungal pesticide from the existing salts. Typically, the salts include acid addition salts of inorganic acids such as hydrochloride, sulfate, nitrate, phosphate, hydrobromide and hydroiodide, or acetates, oxalates, maronates, succinates, marinates, fumarates, lactates, And addition salts of organic acids such as malate, citrate, tartrate, methanesulfonate and ethanesulfonate.
본 발명에서 용어, "피부 주름"이란, 피부가 쇠하여 생긴 잔줄을 의미하는데, 유전자에 의한 원인, 피부 진피에 존재하는 콜라겐의 감소, 외부 환경 등에 의해 유발될 수 있다.In the present invention, the term, “skin wrinkle” refers to a fine line formed due to skin deterioration, which may be caused by a gene, a decrease in collagen present in the dermis of the skin, or an external environment.
본 발명에서 "피부 주름 예방 또는 개선"이란, 피부에 주름이 생성되는 것을 억제 또는 저해하거나, 이미 생성된 주름을 완화시키는 것을 말한다.In the present invention, "prevention or improvement of skin wrinkles" refers to suppressing or inhibiting the formation of wrinkles on the skin, or to relieve wrinkles already generated.
피부 섬유아세포의 주된 기능으로 세포외기질 합성과 증식을 통한 손상된 피부 조직 재생 등을 들 수 있는데, 광노화와 같은 외인성 노화 요인 또는 유리 산소에 의한 손상 누적, 텔로미어 단절로 인한 세포 노화 등에 따른 내인성 노화 요인들은 진피층 내에 있는 피부섬유아세포의 생리 활성 기능을 저하하게 된다. 피부 세포외기질 중 95% 이상을 차지하고, 세포의 부착분자(adhesion molecule) 및 세포 골격(cytoskeleton) 등과의 상호 작용과 신호 교류를 통해 섬유아세포의 생리 활성에 매우 주요한 부분을 담당하는 제I형 콜라겐의 합성이 저하될 경우, 피부 조직 내 콜라겐 양이 감소하고, 이에 따라 표면 장력이 감소하여 피부 탄력이 저하되고 피부 주름이 형성될 뿐만 아니라, 세포의 증식 및 재생 기능을 포함하는 생리 활성 기능이 감소하는 악순환의 원인이 된다.The main function of skin fibroblasts is the regeneration of damaged skin tissue through the synthesis and proliferation of extracellular matrix, such as exogenous aging factors such as photoaging, or accumulation of damage due to free oxygen, and endogenous aging factors due to cell aging due to telomere breakage. They degrade the physiologically active function of skin fibroblasts in the dermal layer. Type I collagen, which accounts for more than 95% of the extracellular matrix of the skin and plays a very important part in the physiological activity of fibroblasts through interaction and signal exchange with cell adhesion molecules and cytoskeleton. When the synthesis of is decreased, the amount of collagen in the skin tissue decreases, and accordingly the surface tension decreases, skin elasticity decreases and skin wrinkles are formed, and physiologically active functions including cell proliferation and regeneration functions decrease. Cause a vicious circle.
따라서, 피부섬유아세포의 콜라겐은 피부 재생, 피부 탄력, 피부 주름 형성 및 피부 손상 시 조직의 수복 또는 재생과 직접적인 관련이 있다고 볼 수 있다.Therefore, it can be considered that collagen of skin fibroblasts is directly related to skin repair, skin elasticity, skin wrinkle formation, and tissue repair or regeneration in case of skin damage.
즉, 피부 섬유아세포의 콜라겐 또는 프로콜라겐의 합성이 촉진되거나, 콜라겐을 분해하는 기질 단백질 분해효소(matrix metallo-proteinase, 이하 'MMP'라 함)의 합성이 저해되면, 피부 탄력 개선, 피부 재생, 피부 주름 개선, 상처 치유, 손상된 피부 조직의 수복 및 재생, 및 피부 노화 방지 등의 효과를 얻을 수 있다.In other words, when the synthesis of collagen or procollagen of skin fibroblasts is accelerated, or the synthesis of matrix metallo-proteinase (hereinafter referred to as 'MMP') that degrades collagen is inhibited, skin elasticity is improved, skin regeneration, It can improve skin wrinkles, heal wounds, repair and regenerate damaged skin tissue, and prevent skin aging.
본 발명의 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올을 유효성분으로 포함하는 조성물은 타입 I 프로콜라겐 유전자의 발현 증가에 시너지 효과가 있고, MMP-1((matrix metallo-proteinase 1) 유전자의 발현 억제에 시너지 효과가 있는 것을 특징으로 한다.The composition comprising the ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol of the present invention as an active ingredient has a synergistic effect on increasing the expression of the type I procollagen gene, MMP-1 ((matrix metallo -proteinase 1) It has a synergistic effect on the suppression of gene expression.
구체적으로, 본 발명의 상기 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올을 포함하는 조성물은 자외선 조사된 정상 인간 진피 섬유아세포(NHDF)에서 세포 독성을 저감시키고, 콜라겐 분해를 촉진하는 기질 단백질 분해효소-1(matrix metallo-proteinase) 유전자의 발현을 억제하는 동시에, 타입 Ⅰ 프로콜라겐 유전자의 발현을 증가시키는데 시너지 효과가 있는바, 피부 탄력 증가, 피부 재생, 피부 주름 개선, 상처 치유, 손상된 피부 조직의 수복 및 재생; 및 피부 노화 방지 등의 효과 등을 가질 수 있다. 구체적으로는 피부 주름의 예방 또는 개선의 효과를 가질 수 있다(도 2 내지 도 7 참조).Specifically, the composition comprising the ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol of the present invention reduces cytotoxicity in normal human dermal fibroblasts (NHDF) irradiated with ultraviolet rays, and degrades collagen It inhibits the expression of the matrix metallo-proteinase-1 (matrix metallo-proteinase) gene, while synergistically increasing the expression of the type I procollagen gene, improving skin elasticity, improving skin regeneration, and improving skin wrinkles. Wound healing, restoration and regeneration of damaged skin tissue; And skin aging prevention. Specifically, it may have an effect of preventing or improving skin wrinkles (see FIGS. 2 to 7).
본 발명의 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올을 유효성분으로 포함하는 화장료 조성물에서, 상기 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올은 1 : 0.5 내지 1.5의 중량비로 혼합되는 것이 바람직하며, 1 : 1의 비율로 혼합되는 것이 가장 바람직하다. 상기 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올은 진세노사이드 F2의 1 중량비 대비 4-알파-D-글루코피라노실록시 벤질 알코올 0.5 내지 1.5의 중량비로 혼합될 때 MMP-1(matrix metallo-proteinase 1) 유전자의 발현 억제에 우수한 효과가 있는 것으로 나타났고, 진세노사이드 F2의 1 중량비 대비 4-알파-D-글루코피라노실록시 벤질 알코올 1의 중량비로 혼합될 때 가장 높은 MMP-1 유전자 발현 억제 활성을 갖는 것으로 측정되었다. 특히, 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올을 1:1의 중량비로 혼합하여 10ug/mL의 용량으로 처리한 실험군에서 나타난 피부 주름 개선 효과는 UVB를 조사하지 않은 음성대조군에서 측정된 MMP-1 단백질 생성 수치를 약간 웃도는 수준으로 관찰되었으며, 이를 통해 진세노사이드 F2의 1 중량비 대비 4-알파-D-글루코피라노실록시 벤질 알코올 0.5 내지 1.5의 중량비로 혼합되는 조합이 갖는 시너지 효과는 매우 우수한 것을 확인할 수 있었다(도 6 참조).In the cosmetic composition comprising the ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol of the present invention as an active ingredient, the ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol Silver is preferably mixed at a weight ratio of 1: 0.5 to 1.5, and most preferably mixed at a ratio of 1: 1. When ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol are mixed in a weight ratio of 4-alpha-D-glucopyranosyloxy benzyl alcohol 0.5 to 1.5 to 1 weight ratio of ginsenoside F2 MMP-1 (matrix metallo-proteinase 1) was found to have an excellent effect on suppressing the expression of the gene, and mixed with a weight ratio of 4-alpha-D-
또한, 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올은 진세노사이드 F2의 1 중량비 대비 4-알파-D-글루코피라노실록시 벤질 알코올 0.5 내지 1.5의 중량비로 혼합될 때 우수한 타입 I 프로콜라겐 유전자의 발현증가 효과가 있는 것으로 나타났고, 진세노사이드 F2의 1 중량비 대비 4-알파-D-글루코피라노실록시 벤질 알코올 1의 중량비로 혼합될 때 가장 높은 타입 I 프로콜라겐 유전자의 발현증가 활성을 갖는 것으로 측정되었다. 특히, 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올을 1:1의 중량비로 혼합하여 10ug/mL의 용량으로 처리한 실험군에서 나타난 피부 주름 개선 효과는 UVB를 조사하지 않은 음성대조군에서 측정된 타입 I 프로콜라겐 단백질 생성 수치를 오히려 웃도는 수준으로 관찰되었으며, 이를 통해 진세노사이드 F2의 1 중량비 대비 4-알파-D-글루코피라노실록시 벤질 알코올 0.5 내지 1.5의 중량비로 혼합되는 조합이 갖는 시너지 효과는 매우 우수한 것으로 확인되었다(도 7 참조).In addition, ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol are mixed in a weight ratio of 4-alpha-D-glucopyranosyloxy benzyl alcohol 0.5 to 1.5 to 1 weight ratio of ginsenoside F2. When it was shown to have an excellent effect of increasing the expression of the type I procollagen gene, the highest type I pro when mixed in a weight ratio of 4-alpha-D-
또한, 본 발명의 피부 주름 예방 또는 개선용 화장료 조성물에 함유된 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올은 그 자체로 피부 주름을 제거하는 효과가 있으며, 기존에 알려진 피부 주름 예방 및 개선에 효과가 있다고 공지된 물질들과 혼합하여 사용해도 피부 주름의 예방 및 개선 효과를 지속해서 유지할 수 있다. In addition, the ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol contained in the cosmetic composition for preventing or improving skin wrinkles of the present invention has an effect of removing skin wrinkles by itself, and is known Even when used in combination with substances known to be effective in preventing and improving skin wrinkles, the prevention and improvement effects of skin wrinkles can be maintained continuously.
이외에도 본 발명의 화장료 조성물은 수용성 비타민, 지용성 비타민, 고분자 펩타이드, 고분자 다당, 스핑고 지질 및 해초 엑기스 등을 더 포함할 수 있다.In addition, the cosmetic composition of the present invention may further include water-soluble vitamins, fat-soluble vitamins, polymer peptides, polymer polysaccharides, sphingo lipids and seaweed extract.
상기 수용성 비타민으로는 화장품에 배합 가능한 것이라면 어떠한 것도 될 수 있으나, 바람직하게는 비타민 B1, 비타민 B2, 비타민 B6, 피리독신, 염산피리독신, 비타민 B12, 판토텐산, 니코틴산, 니코틴산아마이드, 엽산, 비타민C, 비타민 H 등을 들 수 있으며, 그들의 염(티아민염산염, 아스코르빈산나트륨염 등)이나 유도체(아스코르브산-2-인산나트륨염, 아스코르브산-2-인산마그네슘염 등)도 본 발명에서 사용할 수 있는 수용성 비타민에 포함된다. 상기 수용성 비타민은 미생물 변환법, 미생물 배양물의 정제법, 효소법 또는 화학 합성법 등 통상의 방법에 따라 수득할 수 있다.The water-soluble vitamins can be anything as long as they can be blended into cosmetics, preferably vitamin B1, vitamin B2, vitamin B6, pyridoxine, pyridoxine hydrochloride, vitamin B12, pantothenic acid, nicotinic acid, nicotinic acid amide, folic acid, vitamin C, vitamin H Etc., and their salts (thiamine hydrochloride, sodium ascorbate salt, etc.) and derivatives (ascorbic acid-2-phosphate sodium salt, ascorbic acid-2-magnesium phosphate salt, etc.) can also be used in the present invention. Is included in. The water-soluble vitamin can be obtained according to a conventional method such as a microorganism conversion method, a microorganism culture purification method, an enzyme method or a chemical synthesis method.
상기 지용성 비타민으로는 화장품에 배합 가능한 것이라면 어떠한 것도 될 수 있으나, 바람직하게는 비타민 A, 카로틴, 비타민 D2, 비타민 D3, 비타민 E 등을 들 수 있으며, 그들의 유도체(팔미틴산아스코르빈, 스테아르산아스코르빈, 디팔미틴산아스코르빈, 아세트산dl-알파 토코페롤, 니코틴산dl-알파 토코페롤비타민 E, DL-판토테닐알코올, D-판토테닐알코올, 판토테닐에틸에테르 등) 등도 본 발명에서 사용되는 지용성 비타민에 포함된다.The fat-soluble vitamins can be anything as long as they can be blended into cosmetics, preferably vitamin A, carotene, vitamin D2, vitamin D3, vitamin E, etc., and their derivatives (ascorbyl palmitate, ascorbic stearate) Bin, dipalmitic acid ascorbine, dl-alpha tocopherol acetate, dl-alpha tocopherol vitamin E, DL-pantothenyl alcohol, D-pantothenyl alcohol, pantothenyl ethyl ether, etc. are also included in fat-soluble vitamins used in the present invention. do.
상기 고분자 펩타이드로는 화장품에 배합 가능한 것이라면 어떠한 것도 될 수 있으나, 바람직하게는 콜라겐, 가수 분해 콜라겐, 젤라틴, 엘라스틴, 가수 분해 엘라스틴, 케라틴 등을 들 수 있다. 상기 고분자 펩타이드는 미생물 배양액의 정제법, 효소법 또는 화학 합성법 등 통상의 방법에 따라 정제 취득할 수 있으며, 또는 통상 돼지나 소 등의 진피, 누에의 견 섬유 등의 천연물로부터 정제하여 사용할 수 있다.The polymer peptide may be anything as long as it can be blended into cosmetics, and preferably collagen, hydrolyzed collagen, gelatin, elastin, hydrolyzed elastin, keratin, and the like. The polymer peptide may be obtained by purification according to a conventional method such as a purification method of a microbial culture medium, an enzymatic method or a chemical synthesis method, or may be purified from natural substances such as dermis of a pig or a cow, silkworm silk fibers, and the like.
상기 고분자 다당에는 화장품에 배합 가능한 것이라면 어떠한 것도 될 수 있으나, 바람직하게는 히드록시에틸셀룰로오스, 크산탄검, 콘드로이틴 황산 또는 그 염(나트륨염 등) 등을 들 수 있다. 예를 들어, 콘드로이틴 황산 또는 그 염 등은 통상 포유동물이나 어류로부터 정제하여 사용할 수 있다.The polymer polysaccharide may be anything as long as it can be blended into cosmetics, but preferably hydroxyethyl cellulose, xanthan gum, chondroitin sulfate, or a salt thereof (sodium salt, etc.). For example, chondroitin sulfate or a salt thereof can be used after purification from a mammal or fish.
상기 스핑고 지질로는 화장품에 배합 가능한 것이라면 어떠한 것도 될 수 있으나, 바람직하게는 세라마이드, 피토스핑고신, 스핑고당 지질 등을 들 수 있다. 상기 스핑고 지질은 통상 포유류, 어류, 조개류, 효모 또는 식물 등으로부터 통상의 방법에 따라 정제하거나 화학 합성법에 따라 취득할 수 있다.The sphingo lipid may be any compound that can be blended into cosmetics, but preferably, ceramide, phytosphingosine, sphingosaccharide lipid, and the like. The sphingoli lipid can be purified from a mammal, fish, shellfish, yeast or plant according to a conventional method or obtained by a chemical synthesis method.
상기 해초 엑기스로는 화장품에 배합 가능한 것이라면 어떠한 것도 될 수 있으나, 바람직하게는 갈조 엑기스, 홍조 엑기스, 녹조 엑기스 등을 들 수 있으며, 또한, 이들의 해초 엑기스로부터 정제된 칼라기난, 아르긴산, 아르긴산나트륨, 아르긴산칼륨 등도 본 발명에서 사용되는 해초 엑기스에 포함된다. 해초 엑기스는 해초로부터 통상의 방법에 따라 정제하여 취득할 수 있다.The seaweed extract may be anything as long as it can be blended with cosmetics, but preferably, brown seaweed extract, red seaweed extract, green algae extract, etc., and also, colorginan, arginic acid, arginic acid purified from these seaweed extracts Sodium, potassium arginate, etc. are also included in the seaweed extract used in the present invention. Seaweed extract can be obtained by purifying seaweed according to a conventional method.
본 발명의 화장료에는 상기 필수 성분과 더불어 필요에 따라 통상 화장료에 배합되는 다른 성분을 배합할 수 있다.In the cosmetic composition of the present invention, in addition to the above essential ingredients, other ingredients that are usually blended into the cosmetic composition can be added as necessary.
이외에 첨가해도 되는 배합 성분으로서는 유지 성분, 보습제, 에몰리엔트제, 자외선 흡수제, pH 조정제, 향료, 혈행 촉진제, 냉감제, 제한제, 정제수 등을 들 수 있다.Other components that may be added include oils and fats, moisturizers, emollients, ultraviolet absorbers, pH adjusting agents, flavoring agents, blood circulation accelerators, cooling agents, limiting agents, and purified water.
상기 유지 성분으로는 에스테르계 유지, 탄화수소계 유지, 실리콘계 유지, 불소계 유지, 동물 유지, 식물 유지 등을 들 수 있다.Examples of the fats and oils include ester-based fats and oils, hydrocarbon-based fats and fats, silicone-based fats, fluorine-based fats, animal fats, and vegetable fats.
상기 에스테르계 유지로는 트리2-에틸헥산산글리세릴, 2-에틸헥산산세틸, 미리스틴산이소프로필, 미리스틴산부틸, 팔미틴산이소프로필, 스테아르산에틸, 팔미틴산옥틸, 이소스테아르산이소세틸, 스테아르산부틸, 리놀레산에틸, 리놀레산이소프로필, 올레인산에틸, 미리스틴산이소세틸, 미리스틴산이소스테아릴, 팔미틴산이소스테아릴, 미리스틴산옥틸도데실, 이소스테아르산이소세틸, 세바신산디에틸, 아디핀산디이소프로필, 네오펜탄산이소알킬, 트리(카프릴, 카프린산)글리세릴, 트리2-에틸헥산산트리메틸롤프로판, 트리이소스테아르산트리메틸롤프로판, 테트라2-에틸헥산산펜타엘리슬리톨, 카프릴산세틸, 라우린산데실, 라우린산헥실, 미리스틴산데실, 미리스틴산미리스틸, 미리스틴산세틸, 스테아르산스테아릴, 올레인산데실, 리시노올레인산세틸, 라우린산이소스테아릴, 미리스틴산이소트리데실, 팔미틴산이소세틸, 스테아르산옥틸, 스테아르산이소세틸, 올레인산이소데실, 올레인산옥틸도데실, 리놀레산옥틸도데실, 이소스테아르산이소프로필, 2-에틸헥산산세토스테아릴, 2-에틸헥산산스테아릴, 이소스테아르산헥실, 디옥탄산에틸렌글리콜, 디올레인산에틸렌글리콜, 디카프린산프로필렌글리콜, 디카프릴산프로필렌글리콜, 디카프린산네오펜틸글리콜, 디옥탄산네오펜틸글리콜, 트리카프릴산글리세릴, 트리운데실산글리세릴, 트리이소팔미틴산글리세릴, 트리이소스테아르산글리세릴, 네오펜탄산옥틸도데실, 옥탄산이소스테아릴, 이소노난산옥틸, 네오데칸산헥실데실, 네오데칸산옥틸도데실, 이소스테아르산이소세틸, 이소스테아르산이소스테아릴, 이소스테아르산옥틸데실, 폴리글리세린올레인산에스테르, 폴리글리세린이소스테아르산에스테르, 시트르산트리이소세틸, 시트르산트리이소알킬, 시트르산트리이소옥틸, 락트산라우릴, 락트산미리스틸, 락트산세틸, 락트산옥틸데실, 시트르산트리에틸, 시트르산아세틸트리에틸, 시트르산아세틸트리부틸, 시트르산트리옥틸, 말산디이소스테아릴, 히드록시스테아르산 2-에틸헥실, 숙신산디2-에틸헥실, 아디핀산디이소부틸, 세바신산디이소프로필, 세바신산디옥틸, 스테아르산콜레스테릴, 이소스테아르산콜레스테릴, 히드록시스테아르산콜레스테릴, 올레인산콜레스테릴, 올레인산디히드로콜레스테릴, 이소스테아르산피트스테릴, 올레인산피트스테릴, 12-스테알로일히드록시스테아르산이소세틸, 12-스테알로일히드록시스테아르산스테아릴, 12-스테알로일히드록시스테아르산이소스테아릴 등의 에스테르계 등을 들 수 있다.The ester-based fats and oils include tri2-ethylhexanoate glyceryl, 2-ethylhexanoate cetyl, isopropyl myristate, butyl myristate, isopropyl palmitate, ethyl stearate, octyl palmitate, and isocetyl isostearate, Butyl stearate, ethyl linoleate, isopropyl linoleate, ethyl oleate, isocetyl myristate, isostearyl myristate, isostearyl palmitate, octyldodecyl myristate, isocetyl isostearate, diethyl sebacate, Diisopropyl adipate, isoalkyl neopentanoate, tri (capryl, capric acid) glyceryl, tri2-ethylhexanoate trimethylolpropane, triisostearate trimethylolpropane, tetra2-ethylhexanoate pentaelli Slitol, cetyl caprylate, decyl laurate, hexyl laurate, decyl myristate, myristyl myristate, cetyl myristate, stearyl stearate, decyl oleate, ricinooleic acid Cetyl, isostearyl laurate, isotridecyl myristate, isocetyl palmitate, octyl stearate, isocetyl stearate, isodecyl oleate, octyldodecyl oleate, octyldodecyl oleate, isopropyl isoleate, Cetostearyl 2-ethylhexanoate, stearyl 2-ethylhexanoate, hexyl isostearate, ethylene glycol dioctanoate, ethylene glycol dioleate, propylene glycol dicaprate, propylene glycol dicaprylate, neopentyl glycol dicapric acid , Neopentyl glycol dioctanoate, glyceryl tricaprylic acid, glyceryl triundecylate, glyceryl triisopalmitate, glyceryl triisostearate, octyl dodecyl neopentanoate, isostearyl octanoate, octyl isononanoate , Hexyldecyl neodecanoate, octyldodecyl neodecanoate, isocetyl isostearate, isostearyl isostearate, octyldecyl isostearate, polyglyceyl Linoleic acid ester, polyglycerin isostearic acid ester, triisocetyl citrate, triisoalkyl citrate, triisooctyl citrate, lauryl lactate, myristyl lactate, cetyl lactate, octyldecyl lactate, triethyl lactate, acetyl triethyl citrate, Acetyl tributyl citrate, trioctyl citrate, diisostearyl malate, 2-ethylhexyl hydroxystearate, di2-ethylhexyl succinate, diisobutyl adipate, diisopropyl sebacate, dioctyl sebacate, stearic acid Cholesteryl, Cholesteryl isostearate, Cholesteryl hydroxystearate, Cholesteryl oleate, Dihydrocholesteryl oleate, Pitsteryl isostearate, Pitsteryl oleate, 12-Stealoylhydroxy Isoceyl stearate, 12-stealoylhydroxystearate stearyl, 12-stealoylhydroxystearate isostearate And the like ester, such as.
상기 탄화 수소계 유지로는 스쿠알렌, 유동 파라핀, 알파-올레핀올리고머, 이소파라핀, 세레신, 파라핀, 유동 이소파라핀, 폴리부덴, 마이크로 크리스탈린 왁스, 와셀린 등의 탄화 수소계 유지 등을 들 수 있다.Examples of the hydrocarbon-based oil and fat include hydrocarbon-based oils such as squalene, liquid paraffin, alpha-olefin oligomer, isoparaffin, ceresin, paraffin, liquid isoparaffin, polybutene, microcrystalline wax, and petrolatum.
상기 실리콘계 유지로는 폴리메틸실리콘, 메틸페닐실리콘, 메틸시클로폴리실록산, 옥타메틸폴리실록산, 데카메틸폴리실록산, 도데카메틸시클로실록산, 디메틸실록산 메틸세틸옥시실록산 공중합체, 디메틸실록산 메틸스테알록시실록산 공중합체, 알킬 변성 실리콘유, 아미노 변성 실리콘유 등을 들 수 있다.The silicone-based fats and oils include polymethylsilicone, methylphenylsilicone, methylcyclopolysiloxane, octamethylpolysiloxane, decamethylpolysiloxane, dodecamethylcyclosiloxane, dimethylsiloxane methylcetyloxysiloxane copolymer, dimethylsiloxane methylstealoxysiloxane copolymer, and alkyl And modified silicone oils and amino modified silicone oils.
상기 불소계 유지로는 퍼플루오로폴리에테르 등을 들 수 있다.Examples of the fluorine-based fats and oils include perfluoropolyethers.
상기 동물 또는 식물 유지로는 아보카도유, 아르몬드유, 올리브유, 참깨유, 쌀겨유, 대두유, 옥수수유, 유채유, 행인유, 팜핵유, 팜유, 피마자유, 해바라기유, 포도종자유, 면실유, 야자유, 쿠쿠이너트유, 소맥배아유, 쌀 배아유, 시아버터, 월견초유, 마커데이미아너트유, 난황유, 우지, 마유, 밍크유, 오렌지라피유, 호호바유, 캔데리러왁스, 카르나바왁스, 액상 라놀, 경화피마자유 등의 동물 또는 식물 유지를 들 수 있다.The animal or plant oil includes avocado oil, almond oil, olive oil, sesame oil, rice bran oil, soybean oil, corn oil, rapeseed oil, almond oil, palm kernel oil, palm oil, castor oil, sunflower oil, grape seed oil, cottonseed oil, palm oil, Cucumin Nut Oil, Wheat Germ Oil, Rice Germ Oil, Shea Butter, Moon Seed Colostrum, Marker Demi Nut Oil, Yolk Yolk, Uji, Horse Oil, Mink Oil, Orange Rape Oil, Jojoba Oil, Candelary Wax, Carnauba Wax, Liquid Lanol , Animal or vegetable oils such as hardened castor oil.
상기 보습제로는 수용성 저분자 보습제, 지용성 분자 보습제, 수용성 고분자, 지용성 고분자 등을 들 수 있다.Examples of the moisturizing agent include water-soluble low molecular moisturizing agents, fat-soluble molecular moisturizing agents, water-soluble polymers, and fat-soluble polymers.
상기 수용성 저분자 보습제로는 세린, 글루타민, 솔비톨, 만니톨, 피롤리돈-카르복실산나트륨, 글리세린, 프로필렌글리콜, 1,3-부틸렌글리콜, 에틸렌글리콜, 폴리에틸렌글리콜B(중합도 n = 2 이상), 폴리프로필렌글리콜(중합도 n = 2 이상), 폴리글리세린B(중합도 n = 2 이상), 락트산, 락트산염 등을 들 수 있다.The water-soluble low-molecular moisturizing agents include serine, glutamine, sorbitol, mannitol, pyrrolidone-sodium carboxylate, glycerin, propylene glycol, 1,3-butylene glycol, ethylene glycol, polyethylene glycol B (polymerization degree n = 2 or more), And polypropylene glycol (polymerization degree n = 2 or more), polyglycerin B (polymerization degree n = 2 or more), lactic acid, lactic acid salt, and the like.
상기 지용성 저분자 보습제로는 콜레스테롤, 콜레스테롤에스테르 등을 들 수 있다.Examples of the fat-soluble low molecular moisturizing agent include cholesterol and cholesterol ester.
상기 수용성 고분자로는 카르복시비닐폴리머, 폴리아스파라긴산염, 트라가칸트, 크산탄검, 메틸셀룰로오스, 히드록시메틸셀룰로오스, 히드록시에틸셀룰로오스, 히드록시프로필셀룰로오스, 카르복시메틸셀룰로오스, 수용성키틴, 키토산, 덱스트린 등을 들 수 있다.Examples of the water-soluble polymer include carboxyvinyl polymer, polyasparaginate, tragacanth, xanthan gum, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, carboxymethylcellulose, water-soluble chitin, chitosan, dextrin, etc. Can be mentioned.
상기 지용성 고분자로는 폴리비닐피롤리돈 에이코센 공중합체, 폴리비닐피롤리돈 헥사데센 공중합체, 니트로셀룰로오스, 덱스트린지방산에스테르, 고분자 실리콘 등을 들 수 있다.Examples of the fat-soluble polymer include polyvinylpyrrolidone eicosen copolymer, polyvinylpyrrolidone hexadecene copolymer, nitrocellulose, dextrin fatty acid ester, and polymer silicone.
상기 에몰리엔트제로는 장쇄아실글루타민산콜레스테릴에스테르, 히드록시스테아르산콜레스테릴, 12-히드록시스테아르산, 스테아르산, 로진산, 라놀린지방산콜레스테릴에스테르 등을 들 수 있다.Examples of the emollient agent include long-chain acyl glutamate cholesteryl ester, hydroxystearate cholesteryl, 12-hydroxystearic acid, stearic acid, rosin acid, lanolin fatty acid cholesteryl ester, and the like.
상기 자외선 흡수제로는 파라아미노벤조산, 파라아미노벤조산에틸, 파라아미노벤조산아밀, 파라아미노벤조산옥틸, 살리실산에틸렌글리콜, 살리신산페닐, 살리신산옥틸, 살리신산벤질, 살리신산부틸페닐, 살리신산호모멘틸, 계피산벤질, 파라메톡시계피산-2-에톡시에틸, 파라메톡시계피산옥틸, 디파라메톡시계피산모노-2-에틸헥산글리세릴, 파라메톡시계피산이소프로필, 디이소프로필ㆍ디이소프로필계피산에스테르 혼합물, 우로카닌산, 우로카닌산에틸, 히드록시메톡시벤조페논, 히드록시메톡시벤조페논술폰산 및 그 염, 디히드록시메톡시벤조페논, 디히드록시메톡시벤조페논디술폰산나트륨, 디히드록시벤조페논, 테트라히드록시벤조페논, 4-tert-부틸-4'-메톡시디벤조일메탄, 2,4,6-트리아닐리노-p-(카르보-2'-에틸헥실-1'-옥시)-1,3,5-트리아진, 2-(2-히드록시-5-메틸페닐)벤조트리아졸 등을 들 수 있다.Examples of the ultraviolet absorber include paraaminobenzoic acid, ethyl paraaminobenzoate, amyl paraaminobenzoate, octyl paraaminobenzoate, ethylene glycol salicylate, phenyl salicylate, octyl salicylate, benzyl salicylate, butylphenyl salicylate, homomentyl salicylate, Benzyl cinnamon, 2-ethoxyethyl paramethoxy citrate, octyl paramethoxy citrate, mono-2-ethylhexaneglyceryl diparamethoxy citrate, isopropyl para-methoxy citrate, diisopropyl-diisopropyl cinnamic acid ester mixture , Urocanoic acid, ethyl urocanoate, hydroxymethoxybenzophenone, hydroxymethoxybenzophenonesulfonic acid and salts thereof, dihydroxymethoxybenzophenone, dihydroxymethoxybenzophenone sodium disulfonate, dihydroxy Benzophenone, tetrahydroxybenzophenone, 4-tert-butyl-4'-methoxydibenzoylmethane, 2,4,6-trianilino-p- (carbo-2'-ethylhexyl-1'-oxy) -1,3,5-triazine, 2- (2-hi And the like can be mentioned hydroxy-5-methylphenyl) benzotriazole.
상기 pH 조정제로는 시트르산, 시트르산나트륨, 말산, 말산나트륨, 프말산, 프말산나트륨, 숙신산, 숙신산나트륨, 수산화나트륨, 인산일수소나트륨 등을 들 수 있다.Examples of the pH adjusting agent include citric acid, sodium citrate, malic acid, sodium malate, fomal acid, sodium fomalate, succinic acid, sodium succinate, sodium hydroxide, sodium monohydrogen phosphate, and the like.
또한, 이외에 첨가해도 되는 배합 성분은 이에 한정되는 것은 아니며, 또, 상기 어느 성분도 본 발명의 목적 및 효과를 훼손하지 않는 범위 내에서 배합할 수 있지만, 총중량에 대하여 바람직하게는 0.01 내지 5 중량부, 보다 바람직하게는 0.01 내지 3 중량부로 배합될 수 있다.In addition, the compounding components that may be added in addition are not limited to this, and any of the above components can be blended within a range not impairing the objects and effects of the present invention, but preferably 0.01 to 5 parts by weight based on the total weight, More preferably, it may be blended in 0.01 to 3 parts by weight.
본 발명의 조성물을 함유하여 제조된 화장료는 용액, 유화물, 점성형 혼합물 등의 형상을 취할 수 있다.Cosmetics prepared by containing the composition of the present invention may take the form of solutions, emulsions, viscous mixtures, and the like.
또한, 본 발명의 상기 화장료 조성물에 포함되는 성분은 유효성분으로서 상기 성분 이외에 화장료 조성물에 통상적으로 이용되는 성분들을 포함할 수 있으며, 예를 들면, 안정화제, 안료 및 천연향료와 같은 통상적인 보조제 및 담체를 더 포함할 수 있다.In addition, the components included in the cosmetic composition of the present invention may include components commonly used in cosmetic compositions in addition to the above components as an active ingredient, for example, conventional adjuvants such as stabilizers, pigments and natural fragrances, and It may further include a carrier.
본 발명의 조성물은 피부 주름 예방 및 개선 효과가 있는 화장품 또는 세안제 등에 다양하게 이용될 수 있다. The composition of the present invention can be used in various ways, such as cosmetic or face wash, which has the effect of preventing and improving skin wrinkles.
본 발명의 조성물을 첨가할 수 있는 제품으로는, 예를 들어, 스킨로션, 스킨소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스쳐 로션, 영양로션, 맛사지크림, 영양크림, 모이스처크림, 핸드크림, 파운데이션, 에센스, 영양에센스, 마스크팩 등과 같은 화장품류와 비누, 클렌징폼, 클렌징로션, 클렌징크림, 바디로션, 및 바디클린저 등이 있다.As a product to which the composition of the present invention can be added, for example, skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutrition lotion, massage cream, nutrition cream, moisture cream, hand cream , Cosmetics, such as foundation, essence, nutrition essence, mask pack, soap, cleansing foam, cleansing lotion, cleansing cream, body lotion, and body cleanser.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물섬유, 식물섬유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal fibers, plant fibers, wax, paraffin, starch, tracant, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as a carrier component. You can.
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판, 부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder can be used as a carrier component, and in the case of a spray, additionally chlorofluorohydrocarbon, propane , Butane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액의 경우에는 담체 성분으로서 용매, 용매화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or emulsion, a solvent, solvating agent or emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid ester of sorbitan.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, liquid diluents such as water, ethanol or propylene glycol as carrier components, suspensions such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline Cellulose, aluminum metahydroxide, bentonite, agar or trakant, etc. can be used.
본 발명의 다른 양태에 따르면, 본 발명은 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올을 유효성분으로 포함하는 피부 주름 예방 또는 개선용 약학적 조성물을 제공한다.According to another aspect of the present invention, the present invention provides a pharmaceutical composition for preventing or improving skin wrinkles comprising ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol as active ingredients.
또한, 본 발명의 피부 주름 예방 또는 개선용 약학적 조성물에서, 상기 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올은 타입 I 프로콜라겐 유전자의 발현을 증가시키고, MMP-1 유전자의 발현을 억제하는데 시너지 효과가 있는 것을 특징으로 한다.In addition, in the pharmaceutical composition for preventing or improving skin wrinkles of the present invention, the ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol increase the expression of the type I procollagen gene, and MMP-1 It has a synergistic effect in suppressing the expression of genes.
본 발명의 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올을 유효성분으로 포함하는 약학적 조성물에서, 상기 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올은 1 : 0.5 내지 1.5의 중량비로 혼합된 것을 특징으로 한다.In the pharmaceutical composition comprising the ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol of the present invention as an active ingredient, the ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl Alcohol is characterized in that it is mixed in a weight ratio of 1: 0.5 to 1.5.
본 발명의 조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다.The composition of the present invention may further include suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.
본 발명의 조성물의 약학적 투여 형태는 이들의 약학적 허용 가능한 염의 형태로도 사용될 수 있고, 또한 단독으로 또는 타 약학적 활성 화합물과 결합하여 사용될 수 있다.Pharmaceutical dosage forms of the compositions of the present invention may also be used in the form of their pharmaceutically acceptable salts, and may also be used alone or in combination with other pharmaceutically active compounds.
본 발명의 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 올리고당, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. Carriers, excipients and diluents that can be included in the compositions of the present invention include lactose, dextrose, sucrose, oligosaccharides, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium Silicates, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
본 발명의 조성물을 제형화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다.When formulating the composition of the present invention, it is prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, etc., which are usually used.
본 발명의 조성물은 피부에 적용할 수 있는 피부 외용제 제형으로서 크림, 젤, 패취, 분무제, 연고제, 경고제, 로션제, 리니멘트제, 파스타제 또는 카타플라스마제의 피부 외용제 형태로 피부에 직접 투여될 수 있으나, 이에 한정되는 것은 아니다.The composition of the present invention is an external preparation for skin that can be applied to the skin, and is directly applied to the skin in the form of an external preparation for skin such as cream, gel, patch, spray, ointment, warning, lotion, linen agent, pasta, or cataplasma. It may be, but is not limited to this.
본 발명의 혼합 조성물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있으며, 바람직하게는 0.01㎍/㎖ 내지 25㎍/㎖의 용량으로 투여될 수 있다. 외용투여는 하루에 한 번 투여할 수도 있고, 여러 차례 나누어 투여할 수도 있다.The preferred dosage of the mixed composition of the present invention varies depending on the patient's condition and body weight, the degree of disease, the drug form, the administration route and the duration, but can be appropriately selected by those skilled in the art, preferably 0.01 μg / ml to 25 It can be administered in a dose of ㎍ / ㎖. The external administration may be administered once a day, or may be divided into several times.
또 다른 하나의 양태로서, 본 발명은 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올을 유효성분으로 포함하는 피부 주름 예방 또는 개선용 식품 조성물을 제공한다.In another aspect, the present invention provides a food composition for preventing or improving skin wrinkles comprising ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol as active ingredients.
본 발명의 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올을 유효성분으로 포함하는 피부 주름 예방 또는 개선용 식품 조성물에서, 상기 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올은 1 : 0.5 내지 1.5의 중량비로 혼합된 것을 특징으로 한다.In the food composition for preventing or improving skin wrinkles comprising the ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol of the present invention as an active ingredient, the ginsenoside F2 and 4-alpha-D-glu Copyranosyloxy benzyl alcohol is characterized by being mixed in a weight ratio of 1: 0.5 to 1.5.
본 발명의 조성물을 건강기능식품 첨가물로 사용할 경우, 상기 조성물을 그대로 첨가하거나 다른 건강기능식품 또는 건강기능식품 성분과 함께 사용할 수 있고, 통상적인 방법에 따라 적절하게 사용할 수 있다. 유효성분의 혼합량은 사용 목적에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조 시에 본 발명의 조성물은 원료에 대하여 바람직하게는 15 중량부 이하, 더욱 바람직하게는 10 중량부 이하의 양으로 첨가할 수 있다. 그러나, 건강 조절 및 위생을 목적으로 하는 장기 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안정성 면에서 문제가 없으므로 유효성분은 상기 범위 이상의 양으로도 사용할 수 있다.When the composition of the present invention is used as a health functional food additive, the composition may be added as it is or used together with other health functional food or health functional food components, and may be suitably used according to a conventional method. The mixing amount of the active ingredient can be appropriately determined according to the purpose of use. In general, the composition of the present invention in the manufacture of a food or beverage may be added in an amount of preferably 15 parts by weight or less, more preferably 10 parts by weight or less with respect to the raw materials. However, in the case of long-term intake for health control and hygiene purposes, the amount may be below the above range, and since there is no problem in terms of stability, the active ingredient may be used in an amount above the above range.
본 발명의 건강기능식품의 종류에는 특별한 제한은 없다. 상기 조성물을 첨가할 수 있는 건강기능식품의 예로는 육류, 소시지, 빵, 초콜릿, 사탕류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농 제품, 각종 수프, 음료수, 차, 드링크제, 알코올음료 및 비타민 복합제 등이 있고, 통상적인 의미에서의 건강기능식품을 모두 포함할 수 있으며, 동물을 위한 사료로 이용되는 식품을 포함할 수 있다.There are no particular restrictions on the type of health functional food of the present invention. Examples of health functional foods to which the composition can be added are meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, dairy products including gums, ice cream, various soups, beverages, tea, Drinks, alcoholic beverages and vitamin complexes, and the like, may include all of the health functional foods in the ordinary sense, and may include foods used as feed for animals.
또한, 본 발명의 건강기능식품 조성물이 음료의 형태로 사용될 때는 통상의 음료와 같이 여러 가지 감미제, 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상기 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토스, 수크로오스와 같은 디사카라이드, 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 및 자일리톨, 소르비톨, 에리트리톨과 같은 당알코올일 수 있다. 상기 천연 탄수화물의 비율은 이에 제한되지는 않으나, 본 발명의 조성물 100㎖ 당 바람직하게는 약 0.01 내지 0.04g, 더욱 바람직하게는 0.02 내지 0.03g 일 수 있다. 상기 감미제는 타우마틴, 스테비아 추출물과 같은 천연 감미제 및 사카린, 아스파탐과 같은 합성 감미제일 수 있다.In addition, when the health functional food composition of the present invention is used in the form of a beverage, it may contain various sweeteners, flavoring agents, or natural carbohydrates, etc., as additional components, like a conventional beverage. The natural carbohydrate may be monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, dextrins, polysaccharides such as cyclodextrins, and sugar alcohols such as xylitol, sorbitol, and erythritol. The ratio of the natural carbohydrate is not limited thereto, but may be preferably about 0.01 to 0.04 g, more preferably 0.02 to 0.03 g per 100 ml of the composition of the present invention. The sweetener may be a natural sweetener such as taumatin and stevia extract, and a synthetic sweetener such as saccharin and aspartame.
상기 외에 본 발명의 건강기능식품 조성물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 천연 과일쥬스, 과일쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다.In addition to the above, the health functional food composition of the present invention includes various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin , Alcohol, carbonic acid used in carbonated beverages, and the like. In addition, it may contain flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks.
본 발명의 화장료, 약학, 및 식품 조성물은 그 자체적으로 피부 주름 예방 또는 개선의 효과가 있으므로 피부 주름 예방 또는 개선용 조성물로 바로 이용될 수 있고, 피부 주름 예방 및 개선에 효과가 있는 천연 추출물들을 함유하는 다른 성분과 혼합하여 사용하는 형태로도 이용될 수 있어 기존의 피부 주름 예방 또는 개선 효과를 좀 더 높여줄 수 있을 것으로 기대된다.Since the cosmetic, pharmaceutical, and food compositions of the present invention have an effect of preventing or improving skin wrinkles by themselves, they can be used directly as a composition for preventing or improving skin wrinkles, and contain natural extracts that are effective in preventing and improving skin wrinkles. It can be used in the form of mixing with other ingredients to be used, and it is expected that the existing skin wrinkle prevention or improvement effect can be further improved.
이상 설명한 바와 같이, 본 발명의 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올을 유효성분으로 포함하는 조성물은 인간 진피 섬유아세포에서 MMP-1의 발현을 억제하고, 타입 Ⅰ 프로콜라겐의 생성을 증가시키며, IL-6 단백질의 발현을 억제함으로써, 피부 주름의 발생을 예방하고, 손상된 피부의 주름을 개선하는데 시너지 효과를 나타낸다. 종합적으로, 본 발명의 조성물은 피부 주름을 예방하고 크게 개선할 수 있다. As described above, the composition comprising the ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol of the present invention as an active ingredient inhibits the expression of MMP-1 in human dermal fibroblasts, and type I By increasing the production of procollagen and inhibiting the expression of IL-6 protein, it prevents the occurrence of wrinkles on the skin and has a synergistic effect in improving wrinkles on damaged skin. Overall, the composition of the present invention can prevent and greatly improve skin wrinkles.
또한, 본 발명의 조성물은 인체에 매우 안전할 뿐만 아니라, 안정성도 매우 탁월하다.In addition, the composition of the present invention is not only very safe for the human body, but also excellent in stability.
도 1은 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올이 세포 생존에 미치는 영향을 나타낸 그래프이다.
도 2는 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올의 복합 화합물이 갖는 항산화 활성을 나타낸 그래프이다.
도 3은 인간 섬유아세포에서 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올의 복합 화합물이 갖는 MMP-1 단백질의 발현 억제 효과를 나타내는 그래프이다.
도 4는 인간 섬유아세포에서 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올의 복합 화합물이 갖는 타입 I 프로콜라겐 단백질의 발현 촉진 효과를 나타내는 그래프이다.
도 5는 인간 섬유아세포에서 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올의 복합 화합물이 갖는 IL-6 단백질의 발현 억제 효과를 나타내는 그래프이다.
도 6은 배합비율을 달리한 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올의 복합 화합물의 배합비율에 따른 MMP-1 단백질의 발현 억제 효과를 나타내는 그래프이다.
도 7은 배합비율을 달리한 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올의 복합 화합물의 배합비율에 따른 타입 I 프로콜라겐 단백질의 발현 증가 효과를 나타내는 그래프이다.1 is a graph showing the effect of ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol on cell survival.
Figure 2 is a graph showing the antioxidant activity of the complex compound of ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol.
3 is a graph showing the inhibitory effect of the expression of MMP-1 protein on the complex compound of ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol in human fibroblasts.
4 is a graph showing the effect of promoting the expression of type I procollagen protein in a complex compound of ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol in human fibroblasts.
5 is a graph showing the inhibitory effect of IL-6 protein on the complex compound of ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol in human fibroblasts.
6 is a graph showing the effect of inhibiting the expression of MMP-1 protein according to the compounding ratio of the complex compound of ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol with different compounding ratios.
7 is a graph showing the effect of increasing the expression of type I procollagen protein according to the compounding ratio of a complex compound of ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol with different compounding ratios.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하기로 한다. 이들 실시예는 단지 본 발명을 예시하기 위한 것이므로, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지는 않는다.Hereinafter, the present invention will be described in more detail through examples. Since these examples are only for illustrating the present invention, it should not be construed that the scope of the present invention is limited by these examples.
실시예Example 1. 진세노사이드 F2 및 4-알파-D- 1.Ginsenoside F2 and 4-alpha-D- 글루코피라노실록시Glucopyranosyloxy 벤질benzyl 알코올의 제조 Preparation of alcohol
인삼을 정제수로 씻은 후 작은 조각으로 파쇄하고, 건조 중량의 7~8배의 에탄올을 첨가하였다. 100℃에서 2시간 환류시켜 끓인 다음 여과해서 추출액을 얻은 다음 에탄올을 증발하여 인삼 엑기스를 얻었다. 인삼추출 엑기스를 수용성 용매에 용해시키고 미생물 유래의 펙티나아제를 가하고 20-60℃에서 24~72시간 반응시킨 후 진세노사이드 F2가 함유된 아글리콘(aglycon)을 얻었다. 이렇게 얻은 아글리콘(aglycon)을 정제수와 에탄올 혼합용매를 전개 용매로 사용하여 컬럼크로마토그래피로 진세노사이드 F2를 함유하는 분획만을 분취하여 진세노사이드 F2를 제조하였다.After washing the ginseng with purified water, it was crushed into small pieces, and 7-8 times the dry weight of ethanol was added. The mixture was refluxed at 100 ° C. for 2 hours, then filtered to obtain an extract, and then ethanol was evaporated to obtain ginseng extract. Ginseng extract was dissolved in a water-soluble solvent, and pectinase derived from microorganisms was added and reacted at 20-60 ° C for 24 to 72 hours to obtain aglycone containing ginsenoside F2. Glycenoside F2 was prepared by fractionating only the fraction containing ginsenoside F2 by column chromatography using the aglycone thus obtained using a mixed solvent of purified water and ethanol as a developing solvent.
당 공여체로서 전분(soluble starch) 50g과 당 수용체로서 4-하이드록시 벤질알코올(4HBA)을 각각 4.0g을 준비하고, 0.1M CaCl2 용액 1ml에 보관된 CGTase 2,250U과 상기 준비된 당 공여체 및 당 수용체를 0.1M 인산초산 완충용액(pH 6.0)을 가하여 100mL로 정용하였다. 반응액은 50℃의 암소에서 교반하면서 48 시간 반응시킨 다음, 비등 수욕조에서 10분간 가열하여 효소를 불활성화시켰다. 이어서 CGTase와 반응으로 생성된 말토-올리고실글루코시드(malto-oligosylglucoside)들을 모노글루코시드(monoglucoside)로 가수분해시키기 위하여 1.0M 초산 수용액을 사용하여 반응액의 pH를 5.0으로 조절한 다음, 글루코아밀라아제(glucoamylase) 80 유닛(U)을 가하고 50℃에서 교반하면서 8시간 동안 가수분해하였다. 반응액은 비등 수욕조에서 10분간 가열하여 글루코아밀라아제(glucoamylase)를 불활성화시킨 다음 칼럼 크로마토그래피에 의한 반응생성물 분리용 시료로 사용하였다. 50 g of soluble starch as a sugar donor and 4.0 g of 4-hydroxy benzyl alcohol (4HBA) as a sugar acceptor are prepared, and CGTase 2,250U stored in 1 ml of 0.1 M CaCl 2 solution and the prepared sugar donor and sugar acceptor Was added to 0.1M phosphate acetic acid buffer solution (pH 6.0) and dissolved in 100mL. The reaction solution was reacted for 48 hours while stirring in the dark at 50 ° C, and then heated in a boiling water bath for 10 minutes to inactivate the enzyme. Subsequently, in order to hydrolyze malto-oligosylglucosides produced by reaction with CGTase to monoglucoside, the pH of the reaction solution was adjusted to 5.0 using an aqueous 1.0M acetic acid solution, and then glucoamylase (glucoamylase) 80 units (U) were added and hydrolyzed for 8 hours while stirring at 50 ° C. The reaction solution was heated in a boiling water bath for 10 minutes to inactivate glucoamylase, and then used as a sample for separating reaction products by column chromatography.
당 전이반응에 의해 생성된 배당체 분리를 위한 과정의 하나로서 먼저 각각의 반응액에 남아 있는 유리 형태(free form)의 방향족 알코올류를 클로로폼(chloroform)으로 추출하여 제거하였다. 이어서 반응액을 디아이온(Diaion) HP-20 충진 칼럼(3cm × 30cm)에 흡착시킨 다음, 증류수 200mL로 씻어 당류를 제거하고, 메탄올 200mL를 이용하여 생성된 배당체를 용출하였다. 메탄올 용출액을 감압 농축한 다음, 실리카 겔 컬럼 크로마토그래피(silica gel column chromatography)에 의해 추가로 분리하였다. 크로마토그래피는 시료의 약 50배량의 실리카 겔(70~230 mesh)을 글래스 컬럼(3cm×25cm)에 충진한 다음 용매로서 클로로폼-메탄올-물 혼합액(80:20:2, 70:30:3, 65:35;10, v/v)으로 순차 용출시켜 4-알파-D-글루코피라노실록시 벤질 알코올(4-α-D-glucopyranosyloxy benzyl alcohol)을 분리하였다.As one of the processes for the separation of glycosides produced by a sugar transfer reaction, free aromatic aromatic alcohols remaining in each reaction solution were first extracted with chloroform and removed. Subsequently, the reaction solution was adsorbed onto a Diaion HP-20 filling column (3 cm × 30 cm), washed with 200 mL of distilled water to remove saccharides, and the resulting glycosides were eluted using 200 mL of methanol. The methanol eluate was concentrated under reduced pressure, and then further separated by silica gel column chromatography. Chromatography is filled with about 50 times the amount of silica gel (70-230 mesh) of the sample in a glass column (3cm × 25cm), and then a chloroform-methanol-water mixture (80: 20: 2, 70: 30: 3) as a solvent. , 65: 35; 10, v / v) to sequentially dissolve 4-alpha-D-glucopyranosyloxy benzyl alcohol (4-α-D-glucopyranosyloxy benzyl alcohol).
실시예Example 2. 세포 독성 확인 2. Confirmation of cytotoxicity
세포독성은 MTT(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 비색정량분석법(colorimetric assay)을 사용하여 측정하였다. MTT(Methyl thiazol tetrazolium) 분석은 세포 생존 능력을 측정하기 위해 사용되는 것으로, MTT가 보라색을 생성하는 포마르잔 염색으로 바꾸는 것이다. 인큐베이션 72시간 후, 배지의 부피는 1㎖로 감소하였고, 1㎎/㎖ MTT의 100㎕는 각 벽에 첨가되었다. 이후, 세포는 37℃에서 2시간 동안 5%의 CO2 및 95%의 O2 존재 하에 배양되었다. 기질-함유 배지는 제거되었고, 1㎖의 DMSO는 포마르잔 결정을 용해하기 위해 각 벽에 첨가되었다. 또한, 상온에서 30분 동안 오비탈 셰이커로 플레이트를 흔들었다. 100㎕의 부분 표본의 흡수율은 마이크로플레이트 리더(Molecular Devices E09090; 샌프란시스코, CA, 미국)를 사용하여 570㎚에서 흡수율을 측정함으로써 정량화하였다. Cytotoxicity was measured using MTT (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide) colorimetric assay. MTT (Methyl thiazol tetrazolium) analysis is used to measure cell viability, and the MTT is replaced by purple-formed pomarzan staining. After 72 hours of incubation, the volume of the medium was reduced to 1 ml and 100 μl of 1 mg / ml MTT was added to each wall. The cells were then incubated at 37 ° C. for 2 hours in the presence of 5% CO 2 and 95% O 2 . Substrate-containing medium was removed, and 1 ml of DMSO was added to each wall to dissolve formarzan crystals. In addition, the plate was shaken with an orbital shaker for 30 minutes at room temperature. The absorbance of the 100 μl aliquot was quantified by measuring the absorbance at 570 nm using a microplate reader (Molecular Devices E09090; San Francisco, CA, USA).
진세노사이드 F2, 4-알파-D-글루코피라노실록시 벤질 알코올, 및 이들의 조합이 처리된 세포(처리 후 72시간)들의 세포 독성을 확인하고자, UVB 조사된 정상 인간 진피 섬유아세포들에서 MTT 분석을 시행하였다.To confirm the cytotoxicity of cells treated with ginsenoside F2, 4-alpha-D-glucopyranosyloxy benzyl alcohol, and combinations thereof (72 hours after treatment), in normal human dermal fibroblasts irradiated with UVB MTT analysis was performed.
그 결과, 도 1에 나타난 바와 같이, UVB 조사 후, 진세노사이드 F2, 4-알파-D-글루코피라노실록시 벤질 알코올, 및 이들의 복합 화합물의 처리는 인간 진피 섬유상세포들의 세포 생존을 억제하지 않고 오히려 생장을 촉진하는 것을 확인할 수 있었다(도 1).As a result, as shown in FIG. 1, after UVB irradiation, treatment of ginsenoside F2, 4-alpha-D-glucopyranosyloxy benzyl alcohol, and a complex compound thereof inhibits cell survival of human dermal fibroblasts. Instead, it was confirmed that the growth was promoted rather (FIG. 1).
실시예Example 3. 항산화 효과 검증 3. Validation of antioxidant effect
인간 피부 섬유아세포에서 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올의 조합이 갖는 활성산소종(ROS, Reactive Oxygen Species) 생성 억제 효과를 확인하는 실험을 수행하였다. In human skin fibroblasts, an experiment was conducted to confirm the inhibitory effect of ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol on inhibiting the production of reactive oxygen species (ROS).
실험은 인간 피부 섬유아세포에 UVB(UVB Peak range: 312 nm, UV dose: 144 mJ/cm2)를 조사한 다음, 무혈청 DMEM 배지로 희석한 진세노사이드 F2, 4-알파-D-글루코피라노실록시 벤질 알코올, 및 이들의 조합을 농도별(0.1, 1, 10㎍/㎕)로 처리하여 30분 동안 배양하고, 여기(excitation) 480nm, 방출(emission) 530nm 조건에서 형광도를 측정하여 DCF 형광 강도(DCF fluorescence intensity)를 비교하여 수행하였다. 통계처리는 GraphPad Prism 프로그램을 사용하여 실시하였으며, ANOVA(one-way analysis of variance)를 이용하여 평균값의 유의성을 5% 미만의 한계로 조사하였다. Ginsenoside F2, 4-alpha-D-glucopyrano diluted in serum-free DMEM medium after irradiating UVB (UVB Peak range: 312 nm, UV dose: 144 mJ / cm 2 ) to human skin fibroblasts Siloxy benzyl alcohol, and combinations thereof were treated with concentrations (0.1, 1, 10 μg / µl) for 30 minutes to incubate, and fluorescence was measured at excitation 480 nm and emission at 530 nm DCF It was performed by comparing the fluorescence intensity (DCF fluorescence intensity). Statistical processing was performed using the GraphPad Prism program, and the significance of the mean value was investigated to a limit of less than 5% using an one-way analysis of variance (ANOVA).
그 결과, 진세노사이드 F2 또는 4-알파-D-글루코피라노실록시 벤질 알코올의 단독 처리보다 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올의 복합 화합물(1:1 중량비)이 갖는 항산화 효과가 더욱 우수한 것으로 나타났으며, 이러한 현상은 UV 처리된 인간 피부 섬유아세포 실험에서 더욱 뚜렷하게 관찰되었다. 따라서, 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올의 조합은 ROS 생성을 유의하게 억제하고 항산화에 대한 시너지 효과가 있음을 확인할 수 있었다(도 2 참조).As a result, a complex compound of ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol than 1: 1 treatment of ginsenoside F2 or 4-alpha-D-glucopyranosyloxy benzyl alcohol (1: 1 The antioxidant effect of the weight ratio) was found to be more excellent, and this phenomenon was more clearly observed in UV-treated human skin fibroblast experiments. Therefore, it was confirmed that the combination of ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol significantly inhibits ROS production and has a synergistic effect on antioxidant (see FIG. 2).
실시예Example 4. 4. MMPMMP -1 단백질의 합성 저해-1 inhibition of protein synthesis
40mm 세포 배양 접시에 2㎖의 DMEM 배양액을 넣고, 인간 피부 섬유아세포를 약 1.2x105의 농도로 접종한 후, 37℃, 5% CO2 환경에서 24시간 동안 배양하였다. 그 후, UVB를 144mJ/cm2 조건으로 조사한 후, 실시예 1에서 수득한 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올과 이들의 복합 화합물(1:1 중량비, 각각 0.1, 1, 및 10㎍/㎖)을 포함한 배지로 교체하여 3일간 배양하였다. 이후 배양액을 회수(harvest)하여 4℃, 7500rpm 환경에서 5분간 원심분리(centrifuge)하여 ELISA 방법을 이용하여 MMP-1(Human Total MMP-1 kit, R&D Systems, Inc., Minneapolis, MN, USA)의 단백질 발현량 변화를 확인하였다.After adding 2 ml of DMEM culture solution to a 40 mm cell culture dish, human skin fibroblasts were inoculated at a concentration of about 1.2x10 5 , and cultured for 24 hours in a 37 ° C, 5% CO 2 environment. After that, after irradiating UVB at 144 mJ / cm 2 conditions, the ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol obtained in Example 1 and their complex compounds (1: 1 weight ratio, respectively) The medium was replaced with 0.1, 1, and 10 μg / ml) and cultured for 3 days. Thereafter, the culture solution was harvested, and centrifuged for 5 minutes in a 4 ° C, 7500 rpm environment for 5 minutes using ELISA method (Human Total MMP-1 kit, R & D Systems, Inc., Minneapolis, MN, USA) It was confirmed that the protein expression level of the.
먼저, 자외선 조사 없는 인간 피부 섬유아세포 실험에서, 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올의 조합은 MMP-1 단백질의 생성을 농도 의존적으로 억제하고 있음을 알 수 있었다. 0.1, 1, 및 10㎍/㎖ 처리군 모두에서 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올을 동시에 처리한 실험군이 이들의 단독 처리군에 비해 큰 폭으로 개선된 MMP-1 단백질의 생성 저해 효과를 나타내는 것으로 관찰되었으며, 이를 통해 진세노사이드 F2 및 4-알파-D-글루코피라노실록시의 조합에 시너지 효과가 있는 것을 확인할 수 있었다(도 3). First, in a human skin fibroblast experiment without ultraviolet irradiation, it was found that the combination of ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol inhibits the production of MMP-1 protein in a concentration-dependent manner. . The experimental group treated simultaneously with ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol in both 0.1, 1, and 10 μg / mL treatment groups significantly improved MMP compared to their single treatment group. It was observed to show the inhibitory effect on the production of -1 protein, and through this, it was confirmed that there was a synergistic effect on the combination of ginsenoside F2 and 4-alpha-D-glucopyranosyloxy (FIG. 3).
또한, 144mJ/cm2 용량으로 자외선 조사 처리한 인간 피부 섬유아세포는 자외선 무처리군에 비해 MMP-1 단백질의 생성이 4배 이상 증가하였다. 이렇게 자외선 조사 처리로 인한 MMP-1 단백질의 생성 증가는 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올의 복합 화합물 처리로 현저하게 감소하였다. 1, 10, 및 100㎍/㎖ 처리군 모두에서 복합 화합물의 처리가 단독처리군에 비해 큰 폭으로 개선된 MMP-1 단백질의 생성 저해 효과를 나타내는 것으로 관찰되었다(도 3).In addition, in human skin fibroblasts treated with UV irradiation at a dose of 144 mJ / cm 2 , the production of MMP-1 protein was increased four times or more compared to the UV-untreated group. In this way, the increase in the production of MMP-1 protein due to UV irradiation treatment was significantly reduced by treatment with a complex compound of ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol. It was observed that treatment of the complex compound in both 1, 10, and 100 µg / ml treatment groups significantly improved the inhibitory effect of MMP-1 protein production compared to the single treatment group (FIG. 3).
상기와 같은 결과를 통해, 본 발명의 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올의 복합 화합물은 주름생성의 원인이 되는 MMP-1 단백질의 생성을 효과적으로 억제하여 피부 주름의 예방 및 개선에 효과적으로 사용될 수 있었고, 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올의 조합으로 인하여 시너지 효과가 있음을 확인할 수 있었다. Through the above results, the complex compound of ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol of the present invention effectively inhibits the production of MMP-1 protein, which causes wrinkles, thereby reducing skin wrinkles It can be effectively used for the prevention and improvement of, it was confirmed that the synergistic effect due to the combination of ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol.
실시예Example
5. 타입 1 5.
40mm 세포 배양 접시에 2㎖의 DMEM 배양액을 넣고, 인간 피부 섬유아세포를 약 1.2x105의 농도로 접종한 후, 37℃, 5% CO2 환경에서 24시간 동안 배양하였다. 그 후, UVB를 144mJ/cm2 조건으로 조사한 후, 실시예 1에서 제조된 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올 및 이들의 조합(각각 0.1, 1, 및 10㎍/㎖)을 포함한 배지로 교체하여 3일간 배양하였다. 이후 배양액을 회수(harvest)하여 4℃, 7500rpm 환경에서 5분간 원심분리(centrifuge)하여 ELISA 방법을 이용하여 타입 1 프로콜라겐(Procollagen Type I C Peptide EIA Kit, Takara, Shiga, Japan)의 단백질 발현량 변화를 확인하였다.After adding 2 ml of DMEM culture solution to a 40 mm cell culture dish, human skin fibroblasts were inoculated at a concentration of about 1.2x10 5 , and cultured for 24 hours in a 37 ° C, 5% CO 2 environment. After that, UVB was irradiated with 144 mJ / cm 2 conditions, and then ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol prepared in Example 1 and combinations thereof (0.1, 1, and 10, respectively) Μg / ml) and cultured for 3 days. Then, the culture medium was harvested and centrifuged for 5 minutes at 4 ° C and 7500 rpm for 5 minutes to change the protein expression level of the
먼저, 자외선 조사 없는 인간 피부 섬유아세포 실험에서, 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올의 복합 화합물 처리군은 타입 1 프로콜라겐 단백질의 생성을 농도 의존적으로 증가시키고 있음을 알 수 있었다. First, in human skin fibroblast experiments without UV irradiation, the complex compound treatment group of ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol increases the production of
또한, 144mJ/cm2 용량으로 자외선 조사 처리한 인간 피부 섬유아세포는 자외선 무처리군에 비해 타입 1 프로콜라겐 단백질의 생성이 약 3배 정도 감소하였다. 이렇게 자외선 조사 처리로 인한 타입 1 프로콜라겐 단백질의 생성 감소는 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올 복합 화합물의 처리로 다시 증가하는 현상을 나타내었다. 또한, 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올의 복합 화합물 처리군이 이들의 단독처리군에 비해 큰 폭으로 개선된 타입 1 프로콜라겐 단백질의 생성 증가 효과를 나타내는 것으로 관찰되었다(도 4). 상기와 같은 결과를 통해, 본 발명의 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올을 포함하는 조성물은 TGF-β/Smad 신호전달체계에 작용하여 타입 1 프로콜라겐의 생성을 촉진하고, 콜라겐 분해 효소인 MMP-1의 발현을 억제하는 작용을 통해, 주름생성을 효과적으로 예방하며, 생성된 주름을 개선하는 효과가 있음을 확인할 수 있었고, 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올의 조합으로 인하여 시너지 효과가 있음을 확인할 수 있었다. In addition, in human skin fibroblasts treated with UV irradiation at a dose of 144 mJ / cm 2 , the production of
실시예Example 6. IL-6 단백질 발현 억제효과 검증 6. Verification of IL-6 protein expression inhibitory effect
피부세포 손상으로 발생하는 염증반응 메커니즘에서 IL-6 등의 염증 매개 물질들이 관여하게 되며, 염증 매개 물질들의 작용 때문에 염증반응이 증폭되게 되며, IL-6의 발현을 억제하는 경우 염증반응을 효과적으로 차단할 수 있게 된다.In the inflammatory response mechanism caused by skin cell damage, inflammatory mediators such as IL-6 are involved, the inflammatory response is amplified due to the action of the inflammatory mediators, and when the expression of IL-6 is suppressed, the inflammatory response is effectively blocked. It becomes possible.
진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올의 조합이 IL-6 단백질의 발현에 미치는 영향을 검증하기 위해 마우스 대식세포주(mouse macrophage)인 RAW 264.7 세포를 대상을 실험을 수행하였다. RAW 264.7 세포를 96 well plate에 1.0×105 농도로 접종한 후 24시간 동안, 37℃, 5% CO2 습윤 조건 하에서 배양하였다. 이후, PBS 용액으로 세척한 후, 각 well에 LPS 1㎍/㎖을 단독 혹은 다양한 농도의 시료와 함께 처리하고 24시간 동안 배양하였다. 정상 대조군에는 배지만을 처리하였다. In order to verify the effect of the combination of ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol on the expression of IL-6 protein, a mouse macrophage cell RAW 264.7 cell was tested. Was carried out. RAW 264.7 cells were inoculated in a 96 well plate at a concentration of 1.0 × 10 5 and cultured for 24 hours at 37 ° C. under 5% CO 2 wet conditions. Thereafter, after washing with PBS solution, 1 µg / ml of LPS was treated in each well alone or with samples of various concentrations and cultured for 24 hours. In the normal control group, only the medium was treated.
배양이 끝나고, 상등액을 취하여 IL-6 단백질 생성량을 효소결합 면역흡수 분석법(ELISA, Enzyme-Linked Immunosorbent Assay) 키트를 사용하여 분석하였다.After incubation, the supernatant was taken and the amount of IL-6 protein produced was analyzed using an Enzyme-Linked Immunosorbent Assay (ELISA) kit.
그 결과, 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올의 복합 추출물 처리시 LPS로 유도된 IL-6 단백질의 생성이 억제되는 것으로 나타났으며, 이러한 IL-6 단백질 생성 억제능은 농도 의존적인 것으로 나타났다(도 5 참조). 또한, 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올의 복합화합물이 이들의 단독처리군에 비해 큰 폭으로 개선된 IL-6 단백질 생성 억제 효과를 나타내는 것으로 관찰되어, 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올의 조합으로 인하여 시너지 효과가 있음을 확인할 수 있었다.As a result, it was found that the production of IL-6 protein induced by LPS is inhibited when the complex extract of ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol is treated, and this IL-6 protein is produced. The inhibitory ability was found to be concentration dependent (see Figure 5). In addition, it was observed that the complex compound of ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol exhibits a significantly improved IL-6 protein production inhibitory effect compared to those of the single treatment group, It was confirmed that the synergistic effect was due to the combination of cenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol.
실시예Example 7. 진세노사이드 F2 및 4-알파-D- 7. Ginsenoside F2 and 4-alpha-D- 글루코피라노실록시Glucopyranosyloxy 벤질benzyl 알코올의 최적 조합비 도출 Derivation of the optimal combination ratio of alcohol
상기 실시예 3 내지 6의 실험을 통해 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올의 조합이 갖는 피부 주름 개선 및 항산화에 대한 시너지 효과를 확인할 수 있었고, 더 나아가 최적 조합비 도출을 위해 이들의 배합비율을 달리하여 실험하였다. Through the experiments of Examples 3 to 6, the combination of ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol confirmed synergistic effect on skin wrinkle improvement and antioxidant, and furthermore, the optimal combination ratio. For derivation, they were experimented with different mixing ratios.
7-1. 7-1. MMPMMP -1 단백질 합성 저해의 최적 비율Optimal ratio of -1 protein synthesis inhibition
상기 실시예 4의 방법과 동일한 방법으로 수행하되, 상기 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올의 복합 화합물을 10:1 내지 1:10의 중량 비율로 달리하여 실험하였고, 상기 실험은 3회 반복하여 수행되었다. Performed in the same manner as in the method of Example 4, the composite compound of the ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol was tested in a weight ratio of 10: 1 to 1:10. The experiment was repeated three times.
그 결과, 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올의 복합 화합물은 진세노사이드 F2의 1 중량비 대비 4-알파-D-글루코피라노실록시 벤질 알코올 0.5 내지 1.5의 중량비로 혼합될 때 우수한 MMP-1 단백질 생성 억제 효과가 있는 것으로 나타났고, 진세노사이드 F2와 4-알파-D-글루코피라노실록시 벤질 알코올이 1:1의 중량비로 혼합될 때 가장 높은 MMP-1 단백질 생성 억제 활성을 갖는 것으로 측정되었다. As a result, the complex compound of ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol has a ratio of 4-alpha-D-glucopyranosyloxy benzyl alcohol 0.5 to 1.5 to 1 weight ratio of ginsenoside F2. It has been shown to have excellent MMP-1 protein production inhibitory effect when mixed in a weight ratio, and the highest MMP when ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol are mixed in a weight ratio of 1: 1. It was measured to have -1 protein production inhibitory activity.
특히, 진세노사이드 F2와 4-알파-D-글루코피라노실록시 벤질 알코올이 1:1의 중량비로 혼합하여 10㎍/㎖의 용량으로 투여한 실험군에서 나타난 피부주름 개선 효과는 UVB를 조사하지 않은 음성대조군에서 측정된 MMP-1 단백질 생성 수치와 유사한 수준으로 나타났으며, 이를 통해 진세노사이드 F2의 1 중량비 대비 4-알파-D-글루코피라노실록시 벤질 알코올 0.5 내지 1.5의 중량비로 혼합되는 조합이 갖는 시너지 효과는 매우 우수한 것을 확인할 수 있었다(도 6 참조). In particular, ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol were mixed at a weight ratio of 1: 1, and the skin wrinkle improvement effect in the experimental group administered at a dose of 10 µg / ml was not irradiated with UVB. It was found to be at a level similar to the MMP-1 protein production level measured in the non-negative control group, through which it was mixed in a weight ratio of 4-alpha-D-glucopyranosyloxy benzyl alcohol 0.5 to 1.5 to 1 weight ratio of ginsenoside F2. It was confirmed that the synergistic effect of the combination was excellent (see FIG. 6).
7-2. 타입 1 7-2.
상기 실시예 5의 방법과 동일한 방법으로 하되, 상기 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올의 복합 화합물을 10:1 내지 1:10의 중량 비율로 혼합하여 실험하였고, 상기 실험은 3회 반복하여 수행되었다. In the same manner as in Example 5, the composite compound of ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol was mixed and tested in a weight ratio of 10: 1 to 1:10. , The experiment was repeated three times.
그 결과, 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올의 복합 화합물은 진세노사이드 F2의 1 중량비 대비 4-알파-D-글루코피라노실록시 벤질 알코올 0.5 내지 1.5의 중량비로 혼합될 때 우수한 타입 1 프로콜라겐 단백질 생성 촉진 효과가 있는 것으로 나타났고, 진세노사이드 F2와 4-알파-D-글루코피라노실록시 벤질 알코올이 1:1의 중량비로 혼합될 때 가장 높은 타입 1 프로콜라겐 단백질 생성 촉진 활성을 갖는 것으로 측정되었다. As a result, the complex compound of ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol has a ratio of 4-alpha-D-glucopyranosyloxy benzyl alcohol 0.5 to 1.5 to 1 weight ratio of ginsenoside F2. It was found to have
특히, 진세노사이드 F2와 4-알파-D-글루코피라노실록시 벤질 알코올이 1:1의 중량비로 혼합하여 10㎍/㎖의 용량으로 투여한 실험군에서 나타난 피부 주름 개선 효과는 UVB를 조사하지 않은 대조군에서 측정된 타입 1 프로콜라겐 단백질 합성 수치와 유사한 수준으로 나타났으며, 이를 통해 진세노사이드 F2의 1 중량비 대비 4-알파-D-글루코피라노실록시 벤질 알코올 0.5 내지 1.5의 중량비로 혼합되는 조합이 갖는 시너지 효과는 매우 우수한 것을 확인할 수 있었다(도 7 참조). In particular, ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol were mixed at a weight ratio of 1: 1, and the skin wrinkle improvement effect in the experimental group administered at a dose of 10 µg / ml was not irradiated with UVB. It was found to be at a level similar to the
이상으로 본 발명의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현예일 뿐이며, 이에 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다.Since the specific parts of the present invention have been described in detail above, it is clear that for those skilled in the art, this specific technology is only a preferred embodiment, and the scope of the present invention is not limited thereto.
따라서, 본 발명의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다.Accordingly, the substantial scope of the present invention will be defined by the appended claims and their equivalents.
Claims (9)
상기 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올(4-α-D-glucopyranosyloxy benzyl alcohol)는 1 : 0.5 내지 1.5의 중량비로 혼합된 것을 특징으로 하는 피부 주름 예방 또는 개선용 화장료 조성물.Ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol (4-α-D-glucopyranosyloxy benzyl alcohol) as an active ingredient,
The ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol (4-α-D-glucopyranosyloxy benzyl alcohol) is 1: 1 to 0.5 to 1.5 weight ratio of skin wrinkles characterized by being mixed or prevented or improved Cosmetic composition for.
상기 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올(4-α-D-glucopyranosyloxy benzyl alcohol)은 타입 I 프로콜라겐 유전자의 발현을 증가시키고, MMP-1(matrix metallo-proteinase 1) 유전자의 발현을 억제하는 것을 특징으로 하는 피부 주름 예방 또는 개선용 화장료 조성물.According to claim 1,
The ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol (4-α-D-glucopyranosyloxy benzyl alcohol) increase the expression of the type I procollagen gene, MMP-1 (matrix metallo-proteinase 1) Cosmetic composition for preventing or improving skin wrinkles, characterized by suppressing the expression of genes.
상기 조성물은 스킨로션, 스킨소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스쳐 로션, 영양로션, 맛사지크림, 영양크림, 모이스처크림, 핸드크림, 파운데이션, 에센스, 영양에센스, 마스크팩, 비누, 클렌징폼, 클렌징로션, 클렌징크림, 바디로션 및 바디클린저에서 선택된 어느 하나의 제형인 것을 특징으로 하는 피부 주름 예방 또는 개선용 화장료 조성물. According to claim 1,
The composition includes skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutrition lotion, massage cream, nutrition cream, moisture cream, hand cream, foundation, essence, nutrition essence, mask pack, soap, cleansing A cosmetic composition for preventing or improving skin wrinkles, which is a formulation selected from foam, cleansing lotion, cleansing cream, body lotion, and body cleanser.
상기 진세노사이드 F2 및 4-알파-D-글루코피라노실록시 벤질 알코올(4-α-D-glucopyranosyloxy benzyl alcohol)은 1 : 0.5 내지 1.5의 중량비로 혼합된 것을 특징으로 하는 피부 주름 예방 또는 개선용 식품 조성물.
Ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol (4-α-D-glucopyranosyloxy benzyl alcohol) as an active ingredient,
The ginsenoside F2 and 4-alpha-D-glucopyranosyloxy benzyl alcohol (4-α-D-glucopyranosyloxy benzyl alcohol) is 1: 0.5 to 1.5, characterized in that mixed by weight ratio of skin wrinkle prevention or improvement Dragon food composition.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180073853A KR102104803B1 (en) | 2018-06-27 | 2018-06-27 | Composition Comprising Gingenoside F2 and 4-α-D-Glucopyranosyloxy Benzyl Alcohol for Preventing or Improving Skin Wrinkle as Active Ingredient |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180073853A KR102104803B1 (en) | 2018-06-27 | 2018-06-27 | Composition Comprising Gingenoside F2 and 4-α-D-Glucopyranosyloxy Benzyl Alcohol for Preventing or Improving Skin Wrinkle as Active Ingredient |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20200001199A KR20200001199A (en) | 2020-01-06 |
KR102104803B1 true KR102104803B1 (en) | 2020-04-27 |
Family
ID=69158936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180073853A KR102104803B1 (en) | 2018-06-27 | 2018-06-27 | Composition Comprising Gingenoside F2 and 4-α-D-Glucopyranosyloxy Benzyl Alcohol for Preventing or Improving Skin Wrinkle as Active Ingredient |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102104803B1 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101460569B1 (en) * | 2012-07-27 | 2014-11-12 | 강원대학교산학협력단 | Cosmetic composition comprising of gingenoside F2 for skin wrinkle improvement, skin whitening or anti-acne |
KR101953358B1 (en) * | 2016-12-08 | 2019-03-04 | (주)에스디생명공학 | Composition for preventing or improving skin wrinkle comprising α-glucopyranosyloxy benzyl alcohol as active ingredient |
-
2018
- 2018-06-27 KR KR1020180073853A patent/KR102104803B1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR20200001199A (en) | 2020-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101971837B1 (en) | Cosmetic composition for improving skin whitening and wrinkle comprising adventitious root extract of Centella asiatica as effective component | |
KR102042967B1 (en) | Cosmetic composition for anti-aging comprising fucosyllactose | |
KR101948828B1 (en) | Skin repairing, anti-wrinkle or anti-oxidant composition comprising functional peptide, growth factor and citrus peel fermentation product | |
KR20190088286A (en) | Composition for improving skin beauty comprising extract of fermented soybean fermented with Aspergillus cristatus strain | |
KR102236071B1 (en) | Composition for Improving Skin Trouble Using an Extract of Centella asiatica or Paeonia lactiflora Cultured with Magma Seawater | |
KR102319701B1 (en) | Cosmetic composition comprising mixture of fermented extract of Cirsium japonicum and Moringa oleifera | |
KR20210155989A (en) | Composition Comprising Lactobacillus sakei, Culture Fluid, or Culture Fluid Extract thereof with Anti-Wrinkling and Elasticity, Skin Cell Regeneration, and Skin Barrier Property as Active Ingredient | |
KR20200040606A (en) | Composition for anti-oxidation, anti-diabetes, pore shrink or anti-wrinkle comprising extract of Arisoo apple | |
KR102139156B1 (en) | Composition Comprising Enzyme Treated Extract of Red Ginseng and Gastrodia for Preventing or Improving Skin Wrinkle as Active Ingredient | |
KR102104803B1 (en) | Composition Comprising Gingenoside F2 and 4-α-D-Glucopyranosyloxy Benzyl Alcohol for Preventing or Improving Skin Wrinkle as Active Ingredient | |
KR102239415B1 (en) | Composition for improving skin beauty comprising extract of fermented roots of Panax notoginseng by Aspergillus cristatus strain | |
KR102202174B1 (en) | Composition for skin whitening comprising extract of Ruby-S apple peel as an active ingredient | |
KR102290291B1 (en) | Composition for improving moisturizing skin containing fermented blueberry and black rice extracts | |
KR20180114782A (en) | Composition for improving skin beauty comprising extract of fermented Lentinula edodes fermented with Aspergillus cristatus strain | |
KR20230024456A (en) | Composition for skin moisturizing, anti-wrinkle or wound healing comprising ginseng fruit and deer antlers | |
KR20220077991A (en) | Composition for anti-inflammation and anti-wrinkle comprising fermentative product of Gryllus bimaculatus extract as effective component | |
KR101994618B1 (en) | A composition for skin smoothing comprising an extract of fermented ponciri fructus | |
KR101953358B1 (en) | Composition for preventing or improving skin wrinkle comprising α-glucopyranosyloxy benzyl alcohol as active ingredient | |
KR101695372B1 (en) | Composition for improving wrinkle and elasticity containing ribes nigrum extracts | |
KR102652809B1 (en) | Composition for improving skin conditions | |
KR20200040607A (en) | Composition for anti-oxidation, anti-inflammation, anti-diabetes, pore shrink, or anti-wrinkle comprising extract of Summer prince apple | |
KR20200011243A (en) | Composition for anti-oxidation, anti-inflammation, or anti-wrinkle comprising extract of green ball apple peel | |
KR20190053467A (en) | Anti-aging composition comprising culture or its extract of microorganism of serratia genus | |
KR102154140B1 (en) | Composition comprising tulip leaf extract, amorphophallus paeoniifolius hydrolysis extract and parrot ferment extract | |
KR102561258B1 (en) | Composition for controlling sebum and improving pore comprising Jasminum Officinale, Salix Alba (willow) bark and Solanum melogena fruit extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |